<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Interpretation of prostate biopsy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Interpretation of prostate biopsy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Interpretation of prostate biopsy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ximing J Yang, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            W Robert Lee, MD, MS, MEd
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jerome P Richie, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melinda Yushak, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 06, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prostate cancer is the second most common cancer in men worldwide, according to data from the World Health Organization
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgco.iarc.fr%2F&amp;token=papEJRwmxEbzVq8Z5Cy8HpHRmuU6GAJR2OxnHjUvdx0%3D&amp;TOPIC_ID=6924" target="_blank">
          GLOBOCAN
         </a>
         database. The increasing frequency of prostate cancer over the last decade is due in part to widespread screening with serum prostate-specific antigen (figure 1). However, the incidence of the disease was increasing even before the introduction of this test [
         <a href="#rid1">
          1-3
         </a>
         ]. The reasons for this increase are not known; both genetic and environmental factors have been implicated. (See
         <a class="medical medical_review" href="/z/d/html/7567.html" rel="external">
          "Screening for prostate cancer", section on 'Epidemiology and natural history'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6938.html" rel="external">
          "Risk factors for prostate cancer"
         </a>
         .)
        </p>
        <p>
         A histologic diagnosis is required prior to instituting therapy for any stage of prostate cancer. Needle core prostate biopsy under ultrasound guidance is the most common method of obtaining diagnostic tissue. However, with the increasing use of multiparametric magnetic resonance imaging prior to biopsy, targeted fusion biopsies are becoming increasingly common. Other potential sources of diagnostic tissue include material from transurethral resections of the prostate, prostatectomy or cystoprostatectomy specimens, or biopsies from metastatic sites (most often lymph nodes and/or bone).
        </p>
        <p>
         This topic review will discuss the pathology of prostate cancer and the interpretation of the prostate biopsy. Specific issues related to clinical presentation, diagnosis, biopsy, staging, and treatment of prostate cancer are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6939.html" rel="external">
          "Clinical presentation and diagnosis of prostate cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8097.html" rel="external">
          "Prostate biopsy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6943.html" rel="external">
          "Localized prostate cancer: Risk stratification and choice of initial treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          BIOPSY TECHNIQUE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Core needle biopsy of the prostate is essential to determine whether or not cancer is present in men with an elevated serum prostate-specific antigen level and/or an abnormal digital rectal examination. The standard is to take multiple core biopsies, usually under transrectal ultrasound guidance. Primary diagnosis of prostate cancer using fine-needle aspiration is not acceptable in the United States, although it was widely used in other countries in the past. The technique for prostate biopsy and the diagnosis of prostate cancer are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8097.html" rel="external">
          "Prostate biopsy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6939.html" rel="external">
          "Clinical presentation and diagnosis of prostate cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4102808032">
         <span class="h2">
          Issues related to sampling error
         </span>
         <span class="headingEndMark">
          —
         </span>
         Using the standard 12-core biopsy, less than 1 percent of the prostate gland is sampled. This limited sampling explains why a random 12-core biopsy can miss tumor in at least 20 percent of cases and why the Gleason grade may be underestimated in another 20 to 30 percent of cases. Saturation biopsy, using 24 or more cores, has been used to increase the likelihood of identifying areas of tumor [
         <a href="#rid4">
          4
         </a>
         ]. However, this technique may be associated with an increased risk of complications and increased detection of small foci of low-grade carcinoma, which may be clinically insignificant. (See
         <a class="medical medical_review" href="/z/d/html/8097.html" rel="external">
          "Prostate biopsy", section on 'Repeat systematic biopsy'
         </a>
         .)
        </p>
        <p>
         Incorporation of prebiopsy magnetic resonance imaging (MRI) into the diagnostic pathway for a clinically suspected prostate cancer improves the detection of clinically significant disease, reduces adverse effects from biopsy, and can potentially prevent unnecessary biopsies in some individuals. Higher-grade, clinically significant prostatic adenocarcinoma tends to have higher glandular density and a prominent desmoplastic stromal reaction, which can be better detected by MRI [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8097.html" rel="external">
          "Prostate biopsy", section on 'Targeted biopsy'
         </a>
         .)
        </p>
        <p>
         However imaging studies including MRI are not diagnostic tests for prostate cancer and they cannot be used to replace prostate needle core biopsy for establishing the diagnosis of a prostate cancer.
        </p>
        <p>
         Furthermore, MRI-targeted biopsies alone have not replaced the need for standard systematic biopsies because they can miss a significant number of high-grade, clinically significant cancers (Gleason score 7 or above), and there are three major benign conditions, which can be found in negative targeted biopsies that were detected as suspicious lesions on MRI (inflammation, stromal fibrosis, and conditions causing benign increased glandular density such as, benign prostatic hyperplasia). Combining targeted and systematic biopsies offers the best chance of detecting the clinically significant cancer. (See
         <a class="medical medical_review" href="/z/d/html/97482.html" rel="external">
          "The role of magnetic resonance imaging in prostate cancer", section on 'Should males with positive MRI scans only undergo targeted biopsy?'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8097.html" rel="external">
          "Prostate biopsy", section on 'Targeted biopsy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          HISTOLOGIC FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adenocarcinoma accounts for more than 95 percent of malignancies of the prostate. Other types of cancers including neoplasms with neuroendocrine differentiation, urothelial (transitional cell) carcinoma, carcinosarcoma, basal cell carcinoma, lymphomas, or stromal sarcoma do occur within the prostate [
         <a href="#rid6">
          6
         </a>
         ]. The following sections will focus on the diagnostic features of prostatic adenocarcinomas and neuroendocrine neoplasms.
        </p>
        <p>
         Precancerous lesions of the prostate, including prostatic intraepithelial neoplasia (PIN), are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6925.html" rel="external">
          "Precancerous lesions of the prostate: Pathology and clinical implications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H554073675">
         <span class="h2">
          Adenocarcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of prostatic adenocarcinoma, particularly on limited material from needle core biopsy, is based on a constellation of architectural and cytologic features [
         <a href="#rid6">
          6
         </a>
         ], and no single feature is sensitive and specific enough to establish diagnosis of prostatic adenocarcinoma in all cases.
        </p>
        <p>
         Prostatic adenocarcinoma includes acinar and ductal types  (
         <a class="graphic graphic_picture graphicRef76155 graphicRef130804" href="/z/d/graphic/76155.html" rel="external">
          picture 1A-B
         </a>
         ). Acinar adenocarcinoma is much more common than the ductal type [
         <a href="#rid7">
          7
         </a>
         ]. Therefore, most descriptions on prostatic adenocarcinoma refer to acinar type if not specified. Prostatic adenocarcinoma can be diagnosed histologically by the presence of small infiltrating glands with prominent nucleoli. Architecturally, acinar adenocarcinoma cells form glands that are typically smaller than benign glands (acini or ducts  (
         <a class="graphic graphic_picture graphicRef76155" href="/z/d/graphic/76155.html" rel="external">
          picture 1A
         </a>
         )), while ductal adenocarcinoma cells usually form large glands with papillary configurations  (
         <a class="graphic graphic_picture graphicRef130804" href="/z/d/graphic/130804.html" rel="external">
          picture 1B
         </a>
         ).
        </p>
        <p>
         The adenocarcinoma cells, both acinar and ductal types, tend to grow in an infiltrative and haphazard manner  (
         <a class="graphic graphic_picture graphicRef66109" href="/z/d/graphic/66109.html" rel="external">
          picture 2
         </a>
         ). In less differentiated tumors, the glandular pattern is irregular, less organized, fused, or even absent  (
         <a class="graphic graphic_picture graphicRef63504" href="/z/d/graphic/63504.html" rel="external">
          picture 3
         </a>
         ), and the tumor cells tend to grow in as cords, nests, or sheets, more often in cribriform patterns  (
         <a class="graphic graphic_picture graphicRef52604" href="/z/d/graphic/52604.html" rel="external">
          picture 4
         </a>
         ).
        </p>
        <p>
         Cytologically, the cytoplasm of tumor cells is often purple and darker than the pale cytoplasm of the benign epithelium on hematoxylin and eosin (H&amp;E)-stained sections. Tumor cells often display nuclear enlargement, irregularity, and hyperchromasia, and large nucleoli can be seen in the majority of cases  (
         <a class="graphic graphic_picture graphicRef77354" href="/z/d/graphic/77354.html" rel="external">
          picture 5
         </a>
         ). Intraluminal crystalloids, amorphous secretion, or blue-tinged mucin are frequently present in malignant glands but are uncommonly found in benign glands  (
         <a class="graphic graphic_picture graphicRef52171" href="/z/d/graphic/52171.html" rel="external">
          picture 6
         </a>
         ) [
         <a href="#rid6">
          6
         </a>
         ]. The common morphologic features associated with the diagnosis of malignancy as reported in one series of 250 needle biopsies performed at a single institution are listed in the following table  (
         <a class="graphic graphic_table graphicRef59862" href="/z/d/graphic/59862.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Immunohistochemistry
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunohistochemical staining (IHC) may complement histologic examination of H&amp;E-stained tissue sections to confirm a diagnosis of prostate cancer. We often use an IHC "cocktail," which includes alpha-methylacyl-CoA racemase (AMACR; positive in prostate adenocarcinoma), p63, and high molecular weight cytokeratin (34bE12) antibodies (both negative in prostate adenocarcinoma), when diagnostic uncertainty is encountered at the time of a prostate biopsy.
        </p>
        <p>
         IHC for 34bE12 can identify basal cells, which are present in benign prostatic glands but typically absent in prostatic adenocarcinomas [
         <a href="#rid9">
          9,10
         </a>
         ]. This immunostain should be used with caution because some cancer cells are positive and some benign prostatic glands display only weak staining [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         Another molecule, AMACR, also known as P504S, was identified as a molecular marker for prostatic adenocarcinoma by complementary DNA microarray technology [
         <a href="#rid12">
          12-15
         </a>
         ]. Expression of AMACR is a useful marker for tissue diagnosis of prostate cancer in several studies reported by our group  (
         <a class="graphic graphic_picture graphicRef77883" href="/z/d/graphic/77883.html" rel="external">
          picture 7
         </a>
         ) [
         <a href="#rid16">
          16-18
         </a>
         ] and others [
         <a href="#rid14">
          14,15,19
         </a>
         ].
        </p>
        <p>
         More recently, p63, a nuclear protein present in prostatic basal cells and absent in prostatic adenocarcinomas, has also been shown to be a more reliable marker than 34bE12 because of its prominent nuclear staining [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         IHC using prostate-specific antigen (PSA) has a limited role in pathologic diagnosis of prostate cancer on needle biopsy because both adenocarcinomas and benign prostatic epithelium are reactive. On the other hand, PSA IHC may be applied in biopsy material from other organs to confirm the prostatic origin of epithelial cells rather than determining whether they are benign or malignant. PSA-positive cells derived from lymph nodes, bone, or the prostate bed following prostatectomy are more likely to represent malignant cells than are those taken from a core biopsy of an intact prostate.
        </p>
        <p>
         NK3 homeobox 1 (NKX3.1) is a validated prostate-specific marker that has better sensitivity and specificity than PSA [
         <a href="#rid21">
          21,22
         </a>
         ]. In the vast majority of high-grade prostatic adenocarcinomas, the distinct nuclear staining in tumor cells is present  (
         <a class="graphic graphic_picture graphicRef130805" href="/z/d/graphic/130805.html" rel="external">
          picture 8
         </a>
         ). NKX3.1 has been primarily used to determine prostatic origin in a possible metastatic prostate cancer. But on prostate needle core biopsies, its utility is limited because, like PSA, it also labels benign prostatic epithelium.
        </p>
        <p>
         Other prostate-specific markers can be used for diagnostic IHC, including prostate-specific membrane antigen, prostatic-specific acid phosphatase, and Prostein (P501S) [
         <a href="#rid23">
          23-25
         </a>
         ]. They can all be used as a panel of markers to determine a prostatic primary for an individual with a metastatic epithelial tumor, in which a prostatic origin is possible. But, like PSA and NKX3.1, these markers are not cancer specific since they are all present in benign prostatic epithelium.
        </p>
        <p class="headingAnchor" id="H2820442490">
         <span class="h4">
          ERG/TMPRSS2 fusion protein
         </span>
         <span class="headingEndMark">
          —
         </span>
         The erythroblast transformation-specific (ETS) related gene (
         <em>
          ERG
         </em>
         ) is a member of the ETS family of transcription factor genes. A fusion gene between
         <em>
          ERG
         </em>
         and the transmembrane protease, serine 2 (
         <em>
          TMPRSS
         </em>
         ) gene has been found in prostatic adenocarcinoma. ERG protein immunostaining has been used to detect the ERG/TMPRSS2 fusion protein, a product of the fusion gene [
         <a href="#rid26">
          26
         </a>
         ]. In North America, ERG nuclear staining is detected in approximately 50 percent of prostatic adenocarcinoma cases. However, compared with white populations, rates of
         <em>
          ERG/TMPRSS2
         </em>
         gene fusions in prostate cancer are much lower for populations of Black or Asian descent [
         <a href="#rid27">
          27-29
         </a>
         ]. The low sensitivity of ERG immunoreactivity may limit its clinical utility in diagnosis of prostate cancer on needle core biopsies [
         <a href="#rid30">
          30
         </a>
         ]. However, this fusion gene product is fairly specific for prostate cancer [
         <a href="#rid31">
          31
         </a>
         ], and it does have potential diagnostic value in determination of prostatic origin of a metastatic focus, and possibly to differentiate a small cell neuroendocrine carcinoma that arose in the prostate from one arising elsewhere (eg, the lung). (See
         <a class="local">
          'Small cell (neuroendocrine) carcinoma'
         </a>
         below.)
        </p>
        <p>
         Although there are some studies suggesting a role for the
         <em>
          ERG/TMPRSS
         </em>
         fusion gene in prostate cancer progression, more recent reports have not confirmed this finding [
         <a href="#rid32">
          32
         </a>
         ], and ERG expression by itself has not been routinely used in clinical practice for predicting prognosis of prostate cancer. Data on the prognostic influence of combined expression of ERG and loss of phosphatase and tensin homolog are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/94751.html" rel="external">
          "Molecular prognostic tests for prostate cancer", section on 'Phosphatase and tensin homolog loss'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3800860821">
         <span class="h2">
          Neuroendocrine neoplasms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neoplasms with neuroendocrine differentiation arising within the prostate include prostatic adenocarcinoma with neuroendocrine differentiation, well-differentiated neuroendocrine tumors, small cell neuroendocrine carcinoma, and large cell neuroendocrine carcinoma [
         <a href="#rid33">
          33,34
         </a>
         ]. The clinical and prognostic implications of neuroendocrine differentiation are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6943.html" rel="external">
          "Localized prostate cancer: Risk stratification and choice of initial treatment", section on 'High-grade, low-PSA prostate cancer'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H511578292">
         <span class="h3">
          Adenocarcinoma with focal neuroendocrine differentiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many prostatic adenocarcinomas show areas of focal neuroendocrine differentiation using IHC for neuroendocrine markers such as chromogranin, synaptophysin, neuron-specific enolase, or CD56. Typically, the tumor cells that are positive for neuroendocrine markers account only for a small percentage of the total. Neuroendocrine differentiation is not a part of Gleason grading.
        </p>
        <p>
         Focal neuroendocrine differentiation can be observed in several types of prostatic tumors, which may have different biologic and biochemical features [
         <a href="#rid35">
          35-39
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Focal neuroendocrine differentiation may be seen in 47 to 100 percent of cases of typical de novo prostatic adenocarcinomas [
         <a href="#rid37">
          37,38
         </a>
         ], particularly high-grade tumors. The presence of isolated adenocarcinoma cells with large eosinophilic cytoplasmic granules also suggests the presence of neuroendocrine differentiation (also known as Paneth cell differentiation).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Increasingly, IHC is being performed to assess for neuroendocrine markers to search for the presence and document the percentage of neuroendocrine cells in high-grade prostatic adenocarcinoma before any treatment. However, with the exception of treatment-related neuroendocrine prostate cancers, described below, the contribution of focal neuroendocrine differentiation to clinical behavior in de novo prostate adenocarcinoma is uncertain [
         <a href="#rid40">
          40-42
         </a>
         ]. Specifically, focal neuroendocrine differentiation is usually not associated with aggressive clinical behavior, and there is insufficient evidence at this time to support treating these tumors with focal neuroendocrine differentiation differently than typical high-grade prostatic adenocarcinoma. However, pure neuroendocrine carcinomas including small cell carcinoma and large cell neuroendocrine cells are treated differently than conventional prostatic adenocarcinoma. (See
         <a class="local">
          'Small cell (neuroendocrine) carcinoma'
         </a>
         below and
         <a class="local">
          'Large cell (neuroendocrine) carcinoma'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neuroendocrine differentiation may also emerge in men who have previously had androgen deprivation therapy (ADT) for advanced castration-sensitive prostate adenocarcinoma. These tumors, which are referred to as treatment-related neuroendocrine prostatic carcinoma, are an aggressive-variant of prostate cancers and are increasingly recognized in the castration-resistant phases of disease progression [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6945.html" rel="external">
          "Chemotherapy in advanced castration-resistant prostate cancer", section on 'Aggressive prostate cancer variants'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The underlying biology evolves due to the selective pressure of ADT, especially with potent androgen receptor pathway inhibitors. It is possible that a small population of tumor cells with neuroendocrine features present in the untreated prostatic adenocarcinoma were resistant to ADT and became a dominant population after ADT. These tumors can be androgen receptor negative, have a varying degree of histologic features of neuroendocrine cells (such as fine "salt-pepper" chromatin), can express markers of neuroendocrine differentiation (eg, chromogranin, synaptophysin), and may be low in PSA production and negative or weak in other prostatic markers [
         <a href="#rid44">
          44
         </a>
         ]. The presence of these neuroendocrine tumor cells can be associated with an aggressive clinical course with atypical clinical manifestations, and a relative resistance to androgen signaling inhibitors, but possible sensitivity to taxane/platinum combinations. (See
         <a class="medical medical_review" href="/z/d/html/6945.html" rel="external">
          "Chemotherapy in advanced castration-resistant prostate cancer", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4082227726">
         <span class="h3">
          Well-differentiated neuroendocrine tumor
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary well-differentiated neuroendocrine tumors, previously termed carcinoid tumors, are extremely rare in the prostate as a primary [
         <a href="#rid45">
          45
         </a>
         ]. Morphologically similar to the counterpart in the gastrointestinal tract, this tumor is usually positive for neuroendocrine markers and negative for PSA. A well-differentiated neuroendocrine tumor of the prostate also may present with locally advanced disease or even metastasis, but it still has a favorable prognosis [
         <a href="#rid45">
          45,46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2613.html" rel="external">
          "Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Small cell (neuroendocrine) carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Small cell (neuroendocrine) carcinoma, a rare primary tumor of the prostate, is an aggressive and fatal disease [
         <a href="#rid47">
          47
         </a>
         ]. This tumor is currently classified under "neuroendocrine neoplasm" along with other small cell carcinoma of other genitourinary (GU) system in the new World Health Organization (WHO) Classification of Urinary and Male Genital Tumours [
         <a href="#rid34">
          34
         </a>
         ]. Its pathologic diagnosis requires the presence of small, undifferentiated (oat cell) carcinoma cells demonstrating scan cytoplasm, "salt pepper" chromatin, high mitotic, and apoptotic activities. These features are almost identical to pulmonary small cell carcinoma.
        </p>
        <p>
         Typically, small cell carcinoma of the prostate will show positivity for one or multiple neuroendocrine markers (chromogranin, synaptophysin, neuron-specific enolase, and CD56). The prostatic specific markers such as PSA, PSAP, PSMA, and NKX3.1 may be lost partially or completely in prostatic small cell carcinoma. Approximately 50 percent of small cell carcinomas of the prostate coexist with typical adenocarcinomas indicating a dedifferentiation process. In addition, only approximately 50 percent of prostatic small cell carcinomas show TTF1 positivity, this rate is much lower than that of the pulmonary counterpart. Therefore, the coexistence with high-grade prostatic adenocarcinoma, partial expression of prostatic markers including positive ERG [
         <a href="#rid48">
          48,49
         </a>
         ] and/or negative TTF1 [
         <a href="#rid50">
          50,51
         </a>
         ] staining in small cell carcinoma are features suggestive of a primary prostatic small cell carcinoma. (See
         <a class="medical medical_review" href="/z/d/html/4882.html" rel="external">
          "Extrapulmonary small cell cancer", section on 'Prostate ESCC'
         </a>
         .)
        </p>
        <p>
         Pure small cell carcinomas of the prostate are typically resistant to ADT that is typically the first-line treatment for prostatic adenocarcinoma [
         <a href="#rid52">
          52
         </a>
         ], and they are usually approached with platinum-containing chemotherapy similar to pulmonary small cell carcinomas. Because of this important therapeutic distinction, care should be taken to distinguish this entity from prostatic adenocarcinoma with focal neuroendocrine differentiation. (See
         <a class="medical medical_review" href="/z/d/html/6945.html" rel="external">
          "Chemotherapy in advanced castration-resistant prostate cancer", section on 'Aggressive prostate cancer variants'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3338787367">
         <span class="h3">
          Large cell (neuroendocrine) carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Large cell neuroendocrine carcinoma (LCNECA) is an aggressive tumor, which can be found in the prostate as well as other parts of the urinary tract. It is somehow controversial how to classify this tumor. In the past, LCNECA as well as small cell carcinoma of the prostate were previously incorporated into prostate tumors in the 2016 WHO Classification of Urinary and Male Genital Tumours, 4
         <sup>
          th
         </sup>
         Edition [
         <a href="#rid53">
          53
         </a>
         ]. However, in the new 2022 WHO Classification of Urinary and Male Genital Tumours, 5
         <sup>
          th
         </sup>
         Edition [
         <a href="#rid34">
          34
         </a>
         ], LCNECA along with small cell carcinoma and other neuroendocrine tumors were all listed under a separate chapter of "neuroendocrine neoplasms" in the GU system rather than as subsets of prostate tumors. Regardless how to classify these LCNECA, unlike sarcomas or melanomas in the GU system, LCNECA and small cell carcinoma in the prostate often coexist with prostatic adenocarcinoma, representing a dedifferentiation process. They may also retain the expression of some prostatic markers including androgen receptors. More studies are necessary to learn whether LCNECA and small cell carcinoma of the prostate will behave and respond to therapy in a similar way as their counterparts of bladder or other GU organs.
        </p>
        <p>
         LCNECA is composed of cells with prominent neuroendocrine features, including salt-pepper chromatin, high mitotic rate, and neuroendocrine differentiation supported by strong positivity for neuroendocrine markers immunohistochemically  (
         <a class="graphic graphic_picture graphicRef110161" href="/z/d/graphic/110161.html" rel="external">
          picture 9
         </a>
         ). In addition, the tumor cells are much larger and pleomorphic than the tumor cells in small cell carcinoma. The tumors do not show glandular differentiation as adenocarcinoma but often form large nests with peripheral palisading and central necrosis. This tumor may be associated with small cell carcinoma or high-grade adenocarcinoma, or high grade prostatic adenocarcinoma.
        </p>
        <p>
         LCNECA is rare and highly aggressive, and is similar to small cell carcinoma in behavior [
         <a href="#rid54">
          54
         </a>
         ]. However, the clinical experience of optimal management is limited because of its rarity.
        </p>
        <p class="headingAnchor" id="H3533524001">
         <span class="h2">
          Intraductal carcinoma of the prostate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intraductal carcinoma of the prostate (IDCP) is a fairly recently defined entity [
         <a href="#rid55">
          55,56
         </a>
         ]. Although not graded using the Gleason grading system [
         <a href="#rid57">
          57
         </a>
         ], IDCP is an indicator of the presence of high-grade invasive prostatic adenocarcinoma, and it is often associated with high-stage, high-volume invasive disease with a poor prognosis. In general, the presence of IDCP generally warrants definitive aggressive therapy because of its association with high-grade invasive cancer. However, a small subset (5 to 10 percent) of patients who have IDCP alone on biopsy may not have high-grade invasive disease at the time of prostatectomy after the histologic specimen is examined thoroughly.
        </p>
        <p>
         IDCP is defined by the presence of malignant epithelial cells filling large prostatic acinar ducts, with preservation of basal cells forming either (1) solid or dense cribriform patterns or (2) a loose cribriform or micropapillary pattern with either marked nuclear atypia (nuclear size six times normal or larger) or nonfocal comedonecrosis. The controversy lies with the difficulty in distinguishing "neoplastic cells" in high-grade PIN from "malignant cells" in IDCP, and the reproducibility in recognizing "loose cribriform patterns" where IDCP and high-grade PIN may overlap. (See
         <a class="medical medical_review" href="/z/d/html/6925.html" rel="external">
          "Precancerous lesions of the prostate: Pathology and clinical implications", section on 'Prostatic intraepithelial neoplasia'
         </a>
         .)
        </p>
        <p>
         Histologically, the neoplastic cells in IDCP are growing within pre-existing ducts in a noninvasive pattern, similar to high-grade PIN  (
         <a class="graphic graphic_picture graphicRef62418" href="/z/d/graphic/62418.html" rel="external">
          picture 10
         </a>
         ). However, IDCP is associated with a coexisting invasive adenocarcinoma in 90 to 100 percent of cases, unlike high-grade PIN, which is associated with a lower risk for invasive carcinoma.
        </p>
        <p>
         Thus, although morphologically almost identical, IDCP may represent one of two distinct entities:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adjacent advanced invasive prostate cancer, representing "colonization" of high-grade invasive adenocarcinoma into benign prostatic ducts; this accounts for the vast majority of IDCP cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In situ carcinoma when associated with minimal low-grade or noninvasive carcinoma; this accounts for a small subset of IDPC cases.
        </p>
        <p>
        </p>
        <p>
         The molecular basis of IDCP is uncertain. The few studies reporting the molecular changes seen with IDCP likely are not limited to IDCP with adjacent invasive high-grade carcinoma because of the difficulty in dissecting IDCP alone. Although some experts disagree, there is a general consensus that when present, IDCP should not be graded using the Gleason score or grade groups at this time [
         <a href="#rid58">
          58,59
         </a>
         ]. (See
         <a class="local">
          'Gleason grading system'
         </a>
         below.)
        </p>
        <p>
         IDCP by itself is not an aggressive invasive disease, but it could be the product and indicator of highly invasive prostate cancer. As a result, it is an independent predictor for poor prognosis in the vast majority of cases in which it is found. It is more commonly associated with high-grade, mostly acinar-type prostatic adenocarcinoma, and occasionally ductal adenocarcinoma. IDCP is often associated with biologically and clinically aggressive disease with a high risk for advanced tumor stage, high tumor volume, and poor outcomes [
         <a href="#rid58">
          58,60-64
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 21 radical prostatectomies in patients who originally had IDCP on biopsy, the average Gleason score was 7.9 [
         <a href="#rid58">
          58
         </a>
         ]. Pathologic staging in these cases found that 11 (51 percent) had prostatic cancer with extraprostatic extension (pT3), eight (38 percent) had cancer that was confined to the prostate (pT2), and two (10 percent) showed only intraductal carcinoma without invasive cancer.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a systematic review of 31 studies totaling 179,721 patients with localized and advanced prostate cancer, intraductal disease was associated with lower biochemical recurrence-free survival (pooled hazard ratio [HR] 2.09, 95% CI 1.75-2.50) and cancer-specific survival (pooled HR 2.93, 95% CI 2.25-3.81) in men with localized disease [
         <a href="#rid64">
          64
         </a>
         ]. Among men with advanced prostate cancer, overall survival was lower in those with versus without intraductal disease (pooled HR 1.75, 95% CI 1.43-2.14). The presence of intraductal carcinoma was an adverse feature in both prostate biopsies and prostatectomy specimens.
        </p>
        <p>
        </p>
        <p>
         Definitive therapy (prostatectomy, radiation therapy) is recommended in patients with an established diagnosis of IDCP on needle biopsy, even in the absence of pathologically documented invasive prostate cancer on needle biopsy, because of the risk of high-grade, high-stage prostatic adenocarcinoma. (See
         <a class="medical medical_review" href="/z/d/html/6940.html" rel="external">
          "Initial approach to low- and very low-risk clinically localized prostate cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6947.html" rel="external">
          "Initial management of regionally localized intermediate-, high-, and very high-risk prostate cancer and those with clinical lymph node involvement"
         </a>
         .)
        </p>
        <p>
         The presence of intraductal histology is also associated with a higher risk of biochemical recurrence, metastasis, and mortality following treatment of localized prostate cancer [
         <a href="#rid60">
          60,63
         </a>
         ], and it is enriched for oncologic driver mutations. In particular, men with germline breast cancer susceptibility gene mutations may have a higher incidence of IDCP. (See
         <a class="medical medical_review" href="/z/d/html/112282.html" rel="external">
          "Genetic risk factors for prostate cancer", section on 'Aggressive prostate cancer'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Urothelial (transitional cell) carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Urothelial carcinoma involving the prostate is relatively common. However, most of these tumors result from direct extension into prostatic urethra or prostatic ducts from urothelial carcinoma of the urinary bladder; prostate involvement may be identified in 12 to 48 percent of patients who undergo radical cystectomy for a urothelial bladder cancer [
         <a href="#rid65">
          65
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2989.html" rel="external">
          "Clinical presentation, diagnosis, and staging of bladder cancer"
         </a>
         .)
        </p>
        <p>
         Primary urothelial carcinoma of the prostate without bladder involvement is rare. In the older literature, primary urothelial carcinoma of the prostate was estimated to account for 1 to 4 percent of prostatic malignancies [
         <a href="#rid65">
          65
         </a>
         ]. However, these figures were obtained before the radical prostatectomy era, and therefore, the actual incidence may be even lower.
        </p>
        <p>
         Urothelial carcinoma is not infrequent in prostate needle core biopsy because needle biopsy sample areas are mostly in the prostatic peripheral zone  (
         <a class="graphic graphic_figure graphicRef57801" href="/z/d/graphic/57801.html" rel="external">
          figure 1
         </a>
         ). Because of the differences in clinical management, it is important to recognize urothelial carcinoma, which displays morphologic and IHC characteristics different from prostatic adenocarcinoma.
        </p>
        <p>
         Distinguishing primary prostatic urothelial carcinoma from secondary involvement of the prostate by bladder cancer is very difficult on biopsy specimens. Therefore, clinical investigation of the bladder and urinary tract is necessary if urothelial carcinoma is initially detected in the prostate. The presence of prostatic stromal invasion of urothelial carcinoma, which is associated with worse prognosis, should be evaluated in the case of prostatic urothelial carcinoma, in addition to the grade and location of the tumor.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          KEY COMPONENTS OF THE PATHOLOGY REPORT
         </span>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          When cancer is present
         </span>
         <span class="headingEndMark">
          —
         </span>
         The histologic diagnosis of prostate cancer on a biopsy specimen must be made without any uncertainty. Any equivocal diagnostic term, such as "possible," "likely," "suspicious," or "atypical," should not be accepted as a definitive diagnosis of malignancy. Therapy should not be initiated for a patient based upon an equivocal or uncertain diagnosis. (See
         <a class="local">
          'Cases with diagnostic uncertainty'
         </a>
         below.)
        </p>
        <p>
         When prostatic adenocarcinoma is present on needle biopsy, it is not sufficient to simply confirm its presence. The following important features should be included in the pathology report.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Gleason grading system
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Gleason grade is based solely on the architectural features of prostate cancer cells, and correlates closely with clinical behavior. A higher score indicates a greater likelihood of having non-organ-confined disease, as well as a worse outcome after treatment of localized disease [
         <a href="#rid66">
          66,67
         </a>
         ]. Based on the growth pattern and degree of differentiation, tumors are graded from 1 to 5, with grade 1 being the most and grade 5 the least differentiated [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H374972233">
         <span class="h4">
          Gleason score
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Gleason score is derived by adding together the numerical values for the two most prevalent differentiation patterns (a primary grade and a secondary grade). As an example, if a biopsy consists of predominantly grade 3 and secondarily grade 4 disease, the combined score is "3+4" or 7. As more experience has been gained with Gleason grading, pathologists generally will not diagnose prostate cancer with composite Gleason scores of 2 to 5 on needle biopsy; thus, the range of composite Gleason scores on prostate biopsies for clinical practice range Gleason 6 to 10.
        </p>
        <p>
         The Gleason score has been the preferred system for grading tumors and was incorporated as a key prognostic factor in the 2010 tumor, node, metastasis (TNM) staging system for prostate cancer. In the eighth (2017) edition of the TNM staging system, the Gleason score information has been incorporated into the new histologic grade group, which is used in assigning patients to prognostic stage groups  (
         <a class="graphic graphic_table graphicRef110728" href="/z/d/graphic/110728.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef110729" href="/z/d/graphic/110729.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/6943.html" rel="external">
          "Localized prostate cancer: Risk stratification and choice of initial treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H556444073">
         <span class="h4">
          The grade group system
         </span>
         <span class="headingEndMark">
          —
         </span>
         The 2014 International Society of Urological Pathology (ISUP) consensus conference adopted a new five-tier grading system based on the modified Gleason scores  (
         <a class="graphic graphic_table graphicRef107132" href="/z/d/graphic/107132.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid69">
          69
         </a>
         ]. This new grading (ISUP grade group) system, which has been updated [
         <a href="#rid57">
          57
         </a>
         ], is used in the new 2022 World Health Organization classification of prostate tumors [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         The new grade group system is not designed to replace the Gleason grading system; instead, it is based on the Gleason score and provides more accurate risk stratification than the composite Gleason score [
         <a href="#rid70">
          70
         </a>
         ]. Tumors are separated into five categories based on the primary and secondary Gleason pattern. The grade group system was validated in an analysis of over 20,000 patients undergoing radical prostatectomy at five academic centers between 2005 and 2014 [
         <a href="#rid71">
          71,72
         </a>
         ]. In the validation study, there was an increasing risk of prostate cancer mortality with increasing overall grade group [
         <a href="#rid71">
          71
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grade group 1: Gleason score ≤6
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grade group 2: Gleason score 3+4 = 7 (hazard ratio [HR] for death 2.8 relative to grade group 1)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grade group 3: Gleason score 4+3 = 7 (HR 6.0 relative to grade group 1)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grade group 4: Gleason score = 8 (including 4+4 = 8, 3+5 = 8, or 5+3 = 8; HR 7.1 relative to grade group 1)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grade group 5: Gleason scores 9 to 10 (4+5, 5+4, or 5+5; HR 12.7 relative to grade group 1)
        </p>
        <p>
        </p>
        <p>
         In another report, five-year recurrence-free survival rates were 95, 83, 65, 63, and 35 percent, respectively, for grade group 1, 2, 3, 4, and 5 [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
         We recommend the inclusion of the grade group after the Gleason score in the pathology report as the current practice. Typically, we will give Gleason score, then Grade group, and specify the percentage of Gleason 4 tumor component in case of Gleason score 7 (eg, "Prostatic adenocarcinoma, Gleason score 3+4 [Grade group 2, with 30 percent Gleason 4 tumor]").
        </p>
        <p>
         It is important that the pathology report includes the percent of the higher Gleason score component, especially for grade groups 2 and 3 [
         <a href="#rid74">
          74
         </a>
         ]. In the United States, we typically report an individual diagnosis Gleason score (grade group) for each part/container of prostate biopsy specimens, which may be related to billing issues. Therefore, one single case may have multiple Gleason scores from the different parts that were sampled. In other countries, the pathologists may provide a global Gleason score (grade group) for the whole biopsy specimen in addition to the diagnoses for each individual part. This is generally more consistent with the final grading from radical prostatectomies; however, it is not required based on the current consensus [
         <a href="#rid57">
          57,74,75
         </a>
         ].
        </p>
        <p>
         There is no consensus whether the clinical management decision should be based on the highest score (grade group) of one part or on the overall (global) Gleason score (grade group) in a prostate biopsy. However, if Gleason 5 tumor component is present in biopsy such as in 3+5, 4+5, the highest score should be considered primarily. For Gleason score 4+3, 4+4, or 3+4, the decision should be mostly decided on the individual basis considering the focus of these higher grades with 4 tumor component could be very small.
        </p>
        <p>
         A diagnosis of prostate cancer with a single-digit Gleason grade should be avoided. For example, a diagnosis of "prostatic adenocarcinoma, Gleason grade 4" is confusing. It could mean a tumor with Gleason score "2+2" or 4, which is a low-grade tumor with limited aggressive behavior, or it could mean a tumor with Gleason score "4+4" or 8, which is very aggressive. A Gleason score or grade group should be reported even for a single small focus of cancer on needle biopsy [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H528216750">
         <span class="h4">
          Does a grade group 1 lesion represent prostate cancer?
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autopsy studies initially noted that there was a disproportionate number of prostate cancers that never caused any symptoms, and subsequent randomized trials confirmed that a great proportion of cancers diagnosed through prostate-specific antigen (PSA) screening were "clinically insignificant" (ie, very low risk) [
         <a href="#rid77">
          77,78
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7567.html" rel="external">
          "Screening for prostate cancer", section on 'Benefits and harms of screening'
         </a>
         .)
        </p>
        <p>
         The identification of those men who have clinically insignificant prostate cancer has been the center of prostate cancer research for decades. Although debated [
         <a href="#rid79">
          79
         </a>
         ], current definitions of insignificant cancer based on pathologic findings at needle biopsy include grade group 1 cancer, &lt;3 cores with cancer, and ≤50 percent of core involved by cancer. These patients can choose to be followed on an active surveillance program, although significant percentages of cases will progress to higher-grade and higher-volume tumor if not treated; the latent period of progression is uncertain. Because of this, close follow-up with serum PSA, repeat biopsy, and/or magnetic resonance imaging is necessary to detect early progression. (See
         <a class="medical medical_review" href="/z/d/html/6943.html" rel="external">
          "Localized prostate cancer: Risk stratification and choice of initial treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6922.html" rel="external">
          "Active surveillance for males with clinically localized prostate cancer"
         </a>
         .)
        </p>
        <p>
         Grade group 1 prostatic adenocarcinoma of a small volume can thus be considered an early phase of prostate cancer, which can be clinically insignificant. This has led some to question whether prostatic adenocarcinoma grade group 1 should even be considered prostate cancer [
         <a href="#rid73">
          73,80,81
         </a>
         ].
        </p>
        <p>
         Key issues that clarify this confusion include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gleason grading of prostate cancer is based on the architectural features, not cytologic features, of the tumor cells. In other words, Gleason grade 6, Gleason grade 7, and Gleason grade 8 are all composed of malignant cells with similar cytologic features but with different architectural patterns.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The histologic features of Gleason grade 6 adenocarcinoma include uncontrolled cellular proliferation, invasiveness, and the lack of basal cells. All of these are the characteristics of a malignant neoplasm.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Almost all the cases of very low-volume prostate cancer demonstrate Gleason 6 (or lower), which suggests that they are the early phase of prostate cancer.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Only a very small subset of Gleason 6 adenocarcinomas is associated with subsequent development of metastatic disease, and these may represent sampling error in the original needle biopsy. A prostate with biopsy-proven Gleason 6 tumor may harbor occult higher-grade tumors, and these undetected higher-grade tumors can metastasize.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Even in the absence of an undetected higher-grade tumor, with current techniques, the Gleason 6 adenocarcinomas that will versus will not develop recurrent disease cannot be predicted with confidence. Contemporary studies of men with Gleason 6 disease strongly suggest that pure Gleason 6 tumors after radical prostatectomy almost never develop metastases [
         <a href="#rid82">
          82,83
         </a>
         ]. In rare cases, however, the Gleason 6 tumors may extend outside the prostate (ie, pathologic stage III), which increases the risk for recurrence. In a study of 7817 patients undergoing radical prostatectomy, only 7 of 2502 patients (0.3 percent) with Gleason 6 tumors had extraprostatic extension (T3a), and none of the 2502 patients with Gleason 6 tumors had seminal vesicle invasion (T3b) [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the absence of treatment, individuals with Gleason 6 adenocarcinoma may be found to have Gleason 7 or higher-grade, or clinically significant cancer with a higher risk of metastases [
         <a href="#rid84">
          84,85
         </a>
         ]. Although most of these cases can be attributed to initial sampling error, others may represent true disease progression. (See
         <a class="medical medical_review" href="/z/d/html/6922.html" rel="external">
          "Active surveillance for males with clinically localized prostate cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H528216765">
         <span class="h4">
          Gleason 3+4 versus 4+3
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gleason 3+4 and 4+3 were formally grouped as Gleason score 7; however, these groups differ substantially in prognosis and have been divided into grade group 2 and grade group 3, respectively. Men with Gleason 4+3 tumors (where grade 4 is more prevalent than grade 3) have a less favorable outcome than do those with Gleason 3+4 disease, where grade 3 is more prevalent [
         <a href="#rid86">
          86-91
         </a>
         ]. As an example, a multivariate analysis of a single-institution series of 1333 men with Gleason 7 prostate cancer found a significantly increased risk of seminal vesicle invasion in those with Gleason 4+3 disease (20 versus 9 percent, odds ratio 2.26) [
         <a href="#rid91">
          91
         </a>
         ]. This observation appears to be more reliable when applied to a prostatectomy specimen rather than one from a biopsy [
         <a href="#rid92">
          92,93
         </a>
         ]. The new group grading system, as discussed above, separates Gleason score 7 into grade group 2 (Gleason 3+4) and grade group 3 (Gleason 4+3) to address the different risks associated with each group.
        </p>
        <p class="headingAnchor" id="H826500327">
         <span class="h4">
          Gleason 8, grade group 4
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gleason score 8, grade group 4 includes patients with Gleason score 4+4 disease as well as those with Gleason score 3+5 or 5+3 prostate cancer. In a contemporary cohort study, the presence of a component of Gleason grade 5 (either 3+5 or 5+3) was associated with an increased risk of prostate cancer mortality (adjusted HR 2.77, 95% CI 1.13-6.80) compared with Gleason score 4+4 disease [
         <a href="#rid94">
          94
         </a>
         ]. However, more studies with larger cohorts are necessary to validate this finding. However, more studies with larger cohorts are necessary to validate this finding. In our experience, most of these cases should be graded Gleason 4+5 or 5+4 (grade group 5) if sufficient tissue sampling can be done.
        </p>
        <p class="headingAnchor" id="H528216772">
         <span class="h4">
          Tertiary Gleason scores
         </span>
         <span class="headingEndMark">
          —
         </span>
         In some cases, a tumor may contain a small component (&lt;5 percent) of higher-grade tumor in addition to the two predominant patterns; the grade of this minor component is referred to as the tertiary Gleason grade. Traditionally, the tertiary Gleason grade has been noncontributory to the overall Gleason score in biopsy specimens. However, in 2005, the ISUP consensus conference recommended that men with biopsy Gleason score 3+4 or 4+3 prostate cancer and a tertiary pattern 5 should have their cancers classified as Gleason score 8 or 9, respectively [
         <a href="#rid95">
          95
         </a>
         ]. These men have a higher pathologic tumor stage and an increased risk of biochemical and clinical recurrence compared with men who have Gleason score 7 disease without a tertiary grade 5 component [
         <a href="#rid90">
          90,96-98
         </a>
         ]. The 2019 consensus conference on grading of prostatic carcinoma recommended reporting separate tertiary Gleason pattern 4 or 5 only when less than 5 percent of tumor volume in radical prostatectomy specimens. If more than 5 percent, these patterns should be included in the Gleason score [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         For radical prostatectomy specimens, the tertiary pattern should be reported in addition to the Gleason score (eg, "Gleason 4+3 = 7 [grade group 3] with tertiary 5 pattern").
        </p>
        <p>
         The percentage of a tumor consisting of high-grade prostate cancer (ie, combined Gleason pattern 4 or 5) may provide additional prognostic information [
         <a href="#rid99">
          99
         </a>
         ]. In a series of 504 consecutive patients undergoing prostatectomy, an increasing percentage of high-grade tumor was associated with a statistically significant poorer cancer-specific survival.
        </p>
        <p class="headingAnchor" id="H528216779">
         <span class="h4">
          Clinical relevance of Gleason score and grade groups
         </span>
         <span class="headingEndMark">
          —
         </span>
         The numerical Gleason score and grade group are of clinical relevance, and they are a component of the American Joint Committee on Cancer staging system  (
         <a class="graphic graphic_table graphicRef110729" href="/z/d/graphic/110729.html" rel="external">
          table 3
         </a>
         ), and the risk stratification schema of the National Comprehensive Cancer Network that is used to select initial treatment for localized disease  (
         <a class="graphic graphic_table graphicRef118962" href="/z/d/graphic/118962.html" rel="external">
          table 5
         </a>
         ), as well as most nomograms and tables that estimate prognosis based on pretreatment variables (see
         <a class="medical medical_review" href="/z/d/html/6943.html" rel="external">
          "Localized prostate cancer: Risk stratification and choice of initial treatment"
         </a>
         ). Several studies suggest that contemporary Gleason grade readings may be significantly higher than they were 10 years ago [
         <a href="#rid100">
          100-102
         </a>
         ]. The effect of this subtle upgrading of Gleason scores over time could be an apparent improvement in outcome for all categories of men with clinically localized prostate cancer (the so-called Will Rogers phenomenon). This issue has the potential to impact the interpretation of studies that suggest improvements in outcome from treatment over time.
        </p>
        <p>
         However, there can be substantial interobserver variability in the Gleason grading of a biopsy specimen, particularly for pathologists with less experience interpreting prostate biopsies. In a study in which the interpretations from 29 pathologists were compared with that of an expert in prostate cancer pathology on an average of 278 samples, only 68 percent of samples were correctly classified as Gleason score &lt;7, 7, or &gt;7 [
         <a href="#rid103">
          103
         </a>
         ]. Therefore, additional training may be necessary for those pathologists who are unfamiliar with the Gleason grading system.
        </p>
        <p>
         Furthermore, there can also be discrepancies between the Gleason score as determined on the prostate biopsy, and the Gleason score that is determined on the final histologic examination of radical prostatectomy specimens. These discrepancies, usually minor, primarily result from the sampling issues on biopsies. With current combined standard biopsy and targeted biopsy and advanced training, the degree of discrepancies is decreasing. This issue is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8097.html" rel="external">
          "Prostate biopsy", section on 'Targeted biopsy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1802581166">
         <span class="h4">
          Modifications to the Gleason grading system
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several minor modifications to the Gleason grading system were proposed during the 2014 ISUP prostate cancer grading consensus conference. These changes include recognition of certain histologic patterns (eg, cribriform, glomeruloid, or mucinous  (
         <a class="graphic graphic_picture graphicRef107283" href="/z/d/graphic/107283.html" rel="external">
          picture 11
         </a>
         and
         <a class="graphic graphic_picture graphicRef107284" href="/z/d/graphic/107284.html" rel="external">
          picture 12
         </a>
         and
         <a class="graphic graphic_picture graphicRef107285" href="/z/d/graphic/107285.html" rel="external">
          picture 13
         </a>
         )) and are summarized in the table  (
         <a class="graphic graphic_table graphicRef107288" href="/z/d/graphic/107288.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p>
         As an example, invasive cribriform patterns in prostatic adenocarcinoma, either Gleason 4 or Gleason 5 (comedo type), have been recognized as a morphologic biomarker for poor prognosis of prostate cancer [
         <a href="#rid104">
          104
         </a>
         ]. It has even been suggested that the large expansile cribriform patterns (now defined as Gleason pattern 4) in prostatic adenocarcinoma should be distinguished from other Gleason pattern 4 lesions and possibly categorized as Gleason pattern 5. However, there is no consensus currently on how to define these cribriform lesions histologically and how to report them in the pathology report in prostate specimens. More studies are being conducted to further characterize the biologic and biochemical features and clinical implications of these lesions [
         <a href="#rid105">
          105,106
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Side and location of the tumor
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because a partial prostatectomy is not practical, some pathologists do not record which side of the prostate harbors the tumor in core biopsies. However, documentation of tumor side and location is critical for urologists planning to perform focal therapy or a nerve-sparing radical prostatectomy [
         <a href="#rid107">
          107
         </a>
         ]. Based on this information, one or both neurovascular bundles may be spared, with a potentially significant impact on postprostatectomy potency rates. (See
         <a class="medical medical_review" href="/z/d/html/6944.html" rel="external">
          "Radical prostatectomy for localized prostate cancer", section on 'Nerve-sparing approach'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Estimated tumor volume
         </span>
         <span class="headingEndMark">
          —
         </span>
         An estimate of tumor volume (often generically termed the "percentage or the length of positive biopsies") can add clinically significant information to other factors, such as the biopsy Gleason score, in risk stratification, and in predicting outcome following therapy for early stage prostate cancer [
         <a href="#rid108">
          108-112
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6943.html" rel="external">
          "Localized prostate cancer: Risk stratification and choice of initial treatment", section on 'Percentage of positive biopsies'
         </a>
         .)
        </p>
        <p>
         There is no major difference between providing the percentage or length (in mm) of positive cores in determination of the tumor extent; since the core length is typically 10 to 15 mm, the length and percentage can be calculated and exchanged roughly if necessary.
        </p>
        <p>
         Both the number of involved cores and extent of tumor within each core should be included in the pathology report. Tumor involvement within a core can be estimated by measuring either the percentage or the length by millimeter of tumor involvement [
         <a href="#rid108">
          108,109
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Perineural invasion
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of perineural invasion (PNI) in a prostate biopsy should be reported since it represents information that may be used by the clinician in planning therapy  (
         <a class="graphic graphic_picture graphicRef69000" href="/z/d/graphic/69000.html" rel="external">
          picture 14
         </a>
         ) [
         <a href="#rid113">
          113,114
         </a>
         ]. PNI in a core biopsy is an important predictor of pathologic stage, with most [
         <a href="#rid108">
          108,113,115-119
         </a>
         ], but not all [
         <a href="#rid120">
          120
         </a>
         ], studies finding a correlation between PNI on biopsy and extraprostatic extension at the time of prostatectomy. The presence of PNI on pretreatment core biopsy is also associated with a significantly higher likelihood of disease recurrence after radiation therapy [
         <a href="#rid119">
          119,121
         </a>
         ].
        </p>
        <p>
         Finding PNI in a prostatectomy specimen is very common. Although this finding has limited independent predictive value for clinical outcomes, PNI found in a prostatectomy specimen is correlated with a higher volume of prostate cancer in our own experience.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Extraprostatic extension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although extraprostatic extension is usually documented only at the time of radical prostatectomy, direct extension of tumor cells beyond the confines of the prostatic capsule into periprostatic adipose tissue can occasionally be observed in needle biopsy specimens  (
         <a class="graphic graphic_picture graphicRef80254" href="/z/d/graphic/80254.html" rel="external">
          picture 15
         </a>
         ). As an example, in one series of 150 malignant needle biopsy specimens, invasion of fat was only detected in one case  (
         <a class="graphic graphic_table graphicRef59862" href="/z/d/graphic/59862.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         The presence of extraprostatic extension is clinically significant because it changes the tumor stage to a clinical T3 lesion, which constitutes locally advanced disease  (
         <a class="graphic graphic_table graphicRef110728" href="/z/d/graphic/110728.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef110729" href="/z/d/graphic/110729.html" rel="external">
          table 3
         </a>
         ), which may have implications for initial treatment  (
         <a class="graphic graphic_table graphicRef118962" href="/z/d/graphic/118962.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/6947.html" rel="external">
          "Initial management of regionally localized intermediate-, high-, and very high-risk prostate cancer and those with clinical lymph node involvement"
         </a>
         .)
        </p>
        <p>
         Involvement of skeletal muscle, ganglions, or individual nerves by tumor cells should not be considered to represent extraprostatic extension because these structures can also be observed within the normal prostate gland.
        </p>
        <p>
         Seminal vesicles, and their continuation within the prostate (the ejaculatory duct), can sometimes be seen on needle biopsy specimens. The epithelial cells of the seminal vesicles are characterized by the presence of hyperchromatic and pleomorphic nuclei with intracellular golden-brown lipofuscin pigment. A diagnosis of tumor involvement of the seminal vesicles must be made cautiously, unless the biopsy is specifically indicated as from the seminal vesicle. Although targeted biopsy of the seminal vesicle is not a routine component of tumor staging, it is occasionally performed.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Presence of a special subtype of cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Occasionally, the presence of special subtypes of malignant tumor cells may be observed coexisting with conventional prostatic adenocarcinoma. The reason to include these tumor components in the diagnostic report is that they are all associated with a poor prognosis, which may require special management [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         These subtypes or components may include but are not limited to the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ductal adenocarcinoma, characterized by the presence of tall columnar tumor cells  (
         <a class="graphic graphic_picture graphicRef130804" href="/z/d/graphic/130804.html" rel="external">
          picture 1B
         </a>
         ). This tumor type can be present centrally around prostatic urethra, but more frequently as associated with high-grade invasive acinar adenocarcinoma in the peripheral zones. Tumor cells form single or pseudostratified layers, with papillary, large gland, or cribriform configuration, and resemble endometrioid carcinoma or colonic adenocarcinoma. Ductal adenocarcinoma, which differs from intraductal carcinoma that is noninvasive, is a mostly high-grade invasive cancer, and should be graded as Gleason 4 pattern [
         <a href="#rid122">
          122-124
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Small cell carcinoma, characterized by the presence of small cell neuroendocrine components, which should be confirmed using immunohistochemistry (IHC) markers of neuroendocrine differentiation. (See
         <a class="local">
          'Small cell (neuroendocrine) carcinoma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A sarcomatoid component along with the carcinoma (carcinosarcoma or sarcomatoid carcinoma), which is characterized by the presence of high-grade spindle tumor cells in addition to typical carcinomatous components.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          When cancer is absent
         </span>
         <span class="headingEndMark">
          —
         </span>
         Even if invasive cancer cannot be determined with certainty on the diagnostic prostate biopsy, several benign features warrant mention in the pathology report.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h3">
          Prostatic intraepithelial neoplasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of high-grade prostatic intraepithelial neoplasia (PIN) in the needle biopsy specimen is clinically significant and should be included in the report, although it does not represent an invasive cancer.
        </p>
        <p>
         High-grade PIN is believed to be a precursor to prostatic adenocarcinoma. The presence of high-grade PIN traditionally mandates a follow-up core biopsy to rule out the presence of a coexisting cancer. However, contemporary studies have shown that the risk of finding cancer in a patient with isolated high-grade PIN was only slightly higher than that in a patient with a benign prostate biopsy. By contrast, the presence of low-grade PIN is not usually reported because of its lack of clinical significance and possible confusion with high-grade PIN. (See
         <a class="medical medical_review" href="/z/d/html/6925.html" rel="external">
          "Precancerous lesions of the prostate: Pathology and clinical implications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h3">
          Inflammation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inflammation, particularly if it is acute, can contribute to an elevated serum PSA; therefore, its presence should be specified in the pathology report [
         <a href="#rid125">
          125,126
         </a>
         ]. In core biopsy specimens of prostate tissue, a severe inflammatory reaction can mask the diagnostic histologic features of an adenocarcinoma; therefore, extreme care should be taken to exclude the presence of a cancer. Nonspecific granulomatous prostatitis, which is characterized by infiltrates of histiocytes and other inflammatory cells, along with destruction of the prostate glandular structures, can be misdiagnosed as high-grade prostate cancer [
         <a href="#rid127">
          127
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          Infarction
         </span>
         <span class="headingEndMark">
          —
         </span>
         If an infarct is present in biopsy tissue, it should be included in the diagnosis because it could be responsible for an elevated PSA level, presumably as a result of tissue necrosis releasing massive amounts of PSA into the serum. Prostatic infarcts are uncommon, and in the past have only been reported on transurethral resection of the prostate material. However, infarcts may be identified in a small number of prostate core needle biopsies (eg, 2 cases in 2959 biopsies in one series [
         <a href="#rid128">
          128
         </a>
         ]). Histologically, a relatively fresh prostatic infarct is characterized by defined areas of coagulative necrosis, with or without hemorrhage; intermediate-aged infarcts have reactive stroma and epithelium without necrosis, and older infarcts are characterized by replacement of the stroma by dense fibrosis and reparative changes (eg, squamous metaplasia at the infarct edges) [
         <a href="#rid128">
          128
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h3">
          Benign prostatic hyperplasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Another common condition that can contribute to an elevated serum PSA is benign prostatic hyperplasia (BPH) [
         <a href="#rid129">
          129
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6889.html" rel="external">
          "Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia"
         </a>
         .)
        </p>
        <p>
         The "diagnosis" of BPH on a core needle biopsy specimen should be avoided since it may give a false impression that it is the cause of serum PSA elevation. Some pathologists routinely diagnose BPH in every prostate needle biopsy specimen without sufficient histologic evidence. However, BPH cannot be reliably diagnosed in such specimens because histologic diagnosis requires the presence of hyperplastic nodules, which cannot be assessed on needle core tissue [
         <a href="#rid130">
          130
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Cases with diagnostic uncertainty
         </span>
         <span class="headingEndMark">
          —
         </span>
         With advances in knowledge and development of diagnostic markers for prostate cancer, the number of prostate biopsy cases with diagnostic uncertainty have been greatly reduced. However, a definitive diagnosis of cancer can still be difficult in some situations, even for the most experienced pathologists. One of the most common problems encountered is the very small size of the suspicious lesion. Furthermore, the histologic features of prostatic adenocarcinoma are complex and may be subtle. An error in any step of tissue processing, including tissue fixation, dehydration, embedding, and even staining, may interfere with a proper diagnosis.
        </p>
        <p>
         In the situation where the pathologist is suspicious but not totally convinced about a diagnosis of prostate cancer, the term "atypical glands suspicious for, but not diagnostic of, prostatic adenocarcinoma" is often applied. Other pathologists may prefer the diagnostic term "atypical small acinar proliferation (ASAP) suspicious for prostatic adenocarcinoma" [
         <a href="#rid131">
          131
         </a>
         ]. This situation of suspicious cases, approximately representing 5 percent of prostate needle core biopsies [
         <a href="#rid132">
          132
         </a>
         ], is not a pathologic entity, but a diagnostic term.
        </p>
        <p>
         The following options are available for cases with diagnostic uncertainty:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Examine multiple deeper tissue sections, which may show sufficient evidence to permit a definitive diagnosis of cancer.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perform IHC for 34bE12 or p63 (negative for prostatic adenocarcinoma) and AMACR (positive for prostatic adenocarcinoma). However, IHC stains may be false positive or false negative, and the diagnosis of prostatic adenocarcinoma should always be primarily based on the histologic features from hematoxylin and eosin-stained slides, rather than IHC stains alone. (See
         <a class="local">
          'Immunohistochemistry'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rebiopsy of the prostate, if clinically indicated. Approximately one-half of men with atypical or suspicious foci will have cancer identified on repeat biopsy [
         <a href="#rid133">
          133-136
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinically follow the patient as in active surveillance program, if high grade prostate cancer can be safely excluded. Most of the suspicious cases turn out to be Gleason 6 tumors (grade group 1).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1640603907">
         <span class="h2">
          Application of artificial intelligence in detection of prostate cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of computer-based analysis of histologic features of prostate cancer is not new [
         <a href="#rid137">
          137
         </a>
         ]. However, with advances in whole-slide imaging capability and advanced computing technologies, an increasing number of studies of artificial intelligence (AI) in prostate cancer pathology are being undertaken [
         <a href="#rid137">
          137-141
         </a>
         ].
        </p>
        <p>
         One group of investigators has reported their findings using an AI software system (Paige Prostate) for detecting prostate cancer [
         <a href="#rid139">
          139
         </a>
         ]. In this study of 1876 whole slide images of prostate core biopsy specimens, the use of the AI software showed high sensitivity (97.7 percent) and high specificity (99.3 percent) in detecting prostate cancer. Notably, Paige Prostate may be more beneficial to nonspecialist pathologists because they were as accurate in making a diagnosis when using Paige as prostate cancer specialists who were not using Paige.
        </p>
        <p>
         Largely based on this study, in September 2021, the United States (US) Food and Drug Administration (FDA) approved the Paige Prostate system, to assist pathologists in making better and more accurate histologic diagnosis of prostate cancer [
         <a href="#rid142">
          142
         </a>
         ].
        </p>
        <p>
         Although there are still questions about current AI systems and whether it can distinguish 1) treated prostate cancer, which displays many other histologic changes; 2) many benign mimickers of prostate cancer; and 3) so called "atypical" lesions in the prostate core biopsy. More studies are necessary clarify these issues.
        </p>
        <p>
         Therefore, in our view, the Paige or other AI systems cannot be used to replace diagnosis by pathologists at this point, but rather enhance the efficiency and accurate of pathology diagnosis of prostate cancer.
        </p>
        <p>
         There are several AI systems for detection prostate cancer on tissue sections from companies in the United States and elsewhere [
         <a href="#rid143">
          143
         </a>
         ]. None have been routinely used in clinical practice in the United States or worldwide, and the Paige system is the first and only one that has received FDA approval in the United States. It is anticipated that more AI systems will be approved in the coming years for assistance of diagnosis and predication of prognosis of prostate cancer.
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          EFFECT OF TREATMENT ON BIOPSY SPECIMENS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several factors can have a significant effect on the histologic appearance of a prostate biopsy specimen  (
         <a class="graphic graphic_table graphicRef50546" href="/z/d/graphic/50546.html" rel="external">
          table 7
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Hormone therapies
         </span>
        </p>
        <p class="headingAnchor" id="H3728472212">
         <span class="h3">
          Androgen ablation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Androgenic influences are important for both the growth and malignant transformation of prostatic tissue. The testes account for 90 to 95 percent of total circulating testosterone, while the adrenal glands produce the remainder. In the prostate, testosterone is converted into dihydrotestosterone (DHT) by the enzyme 5-alpha reductase. DHT is the primary androgen that stimulates the growth of both benign and malignant prostate tissues.
        </p>
        <p>
         Palliation of metastatic disease can be achieved by androgen deprivation therapy (ADT), which can be accomplished surgically (orchiectomy) or medically by administration of gonadotropin-releasing hormone (GnRH) agonists, GnRH antagonists, or androgen receptor blockers (antiandrogens). Although usually reserved for the treatment of advanced or metastatic prostate cancer, ADT may be used in men with less advanced disease (ie, clinically organ-confined or locally advanced) as an adjunct to radiation therapy (RT) or surgery. (See
         <a class="medical medical_review" href="/z/d/html/6951.html" rel="external">
          "Initial systemic therapy for advanced, recurrent, and metastatic noncastrate (castration-sensitive) prostate cancer"
         </a>
         .)
        </p>
        <p>
         A short course of systemic ADT may be administered after the diagnosis of prostate cancer but before local therapy such as radical prostatectomy. Although this therapy is not widely accepted in the United States as a standard therapy, it is being used more commonly for special circumstances, especially during the COVID-19 pandemic as a means of postponing radical prostatectomy. (See
         <a class="medical medical_review" href="/z/d/html/128993.html" rel="external">
          "COVID-19: Considerations in patients with cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6947.html" rel="external">
          "Initial management of regionally localized intermediate-, high-, and very high-risk prostate cancer and those with clinical lymph node involvement", section on 'Neoadjuvant ADT approaches'
         </a>
         .)
        </p>
        <p>
         Neoadjuvant ADT affects the appearance of the prostate cancer at the time of subsequent surgery. Histologically, following a short course of neoadjuvant ADT, prostatic adenocarcinoma cells undergo the same degenerative changes including atrophy and cytoplasmic vacuolation as are seen in men undergoing continuous ADT for advanced prostate cancer  (
         <a class="graphic graphic_picture graphicRef77354" href="/z/d/graphic/77354.html" rel="external">
          picture 5
         </a>
         ). Generally speaking, however, these histologic changes are milder compared with those seen in men undergoing prolonged periods of ADT.
        </p>
        <p>
         Regardless of the duration of ADT, the histologic changes in the prostate gland in prostatectomy specimens are indistinguishable. The effects can be shown both in normal secretory epithelium and in adenocarcinoma cells, the vast majority of which maintain the secretory epithelial phenotype  (
         <a class="graphic graphic_table graphicRef50546" href="/z/d/graphic/50546.html" rel="external">
          table 7
         </a>
         ) [
         <a href="#rid144">
          144,145
         </a>
         ]. Regression and degenerative changes, such as pyknotic nuclei, clear cytoplasm, or vacuolated cytoplasm, are evident, while the features of cytologic atypia (eg, nuclear enlargement and prominent nucleoli) that are typically present in adenocarcinoma cells are diminished or absent. These changes can cause difficulty in assessment of prostate biopsies and may result in underestimation of the extent of disease if hormone therapy was administered prior to a biopsy or prostatectomy. Furthermore, because of the severe histologic changes in tumor cells caused by prior hormonal therapy, the assignment of a Gleason score may not be reliable in this situation and is often withheld. However, it is a challenge for histologic assessment of treated prostate cancer and predication of its biologic behavior. The issue of grading treated prostate cancer should be revisited with more contemporary studies.
        </p>
        <p>
         Despite this, the infiltrating pattern of a prostatic adenocarcinoma is mostly retained and can be recognized. In particular, identification of scattered individual malignant epithelial cells in the stroma is diagnostic evidence of prostatic adenocarcinoma  (
         <a class="graphic graphic_picture graphicRef69529" href="/z/d/graphic/69529.html" rel="external">
          picture 16
         </a>
         ). Immunostaining for keratins or for prostate-specific antigen (PSA) may be helpful in identifying the individual tumor cells in this situation to confirm the diagnosis [
         <a href="#rid146">
          146
         </a>
         ].
        </p>
        <p>
         Other nonspecific histologic changes, including basal cell hyperplasia, transitional cell and squamous cell metaplasia in benign epithelium, and chronic inflammation, may also be present. These nonspecific histologic changes in benign prostatic epithelial cells often provide the pathologist with a clue as to the use of prior hormonal therapy.
        </p>
        <p>
         As noted above, advanced prostate adenocarcinomas can evolve, under the pressure of androgen deprivation therapy, to develop neuroendocrine differentiation (so-called treatment-related neuroendocrine prostate cancer or aggressive-variant prostate cancer). (See
         <a class="local">
          'Adenocarcinoma with focal neuroendocrine differentiation'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h3">
          5-alpha reductase inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The 5-alpha reductase inhibitors,
         <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">
          finasteride
         </a>
         and
         <a class="drug drug_general" data-topicid="8672" href="/z/d/drug information/8672.html" rel="external">
          dutasteride
         </a>
         , which are widely used in the treatment of benign prostatic hyperplasia, are considered to be weak antiandrogens. (See
         <a class="medical medical_review" href="/z/d/html/6891.html" rel="external">
          "Medical treatment of benign prostatic hyperplasia", section on '5-alpha reductase inhibitors'
         </a>
         .)
        </p>
        <p>
         Both
         <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">
          finasteride
         </a>
         and
         <a class="drug drug_general" data-topicid="8672" href="/z/d/drug information/8672.html" rel="external">
          dutasteride
         </a>
         appear to have a limited effect on the histologic appearance of prostatic adenocarcinomas in biopsy specimens in contrast to the steroidal antiandrogens  (
         <a class="graphic graphic_table graphicRef50546" href="/z/d/graphic/50546.html" rel="external">
          table 7
         </a>
         ) [
         <a href="#rid147">
          147-151
         </a>
         ]. Therefore, the histologic diagnosis of prostate cancer on biopsy specimens from men receiving finasteride or dutasteride is not difficult.
        </p>
        <p>
         However, it has been suggested that 5-alpha reductase inhibitors have the potential to alter the Gleason score of prostate cancers [
         <a href="#rid152">
          152
         </a>
         ]. This hypothesis was proposed largely to explain the findings of the Prostate Cancer Prevention Trial, in which men treated with
         <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">
          finasteride
         </a>
         had fewer prostate cancers overall but significantly more tumors of Gleason score 7 to 10 than the control group [
         <a href="#rid153">
          153
         </a>
         ]. However, this observation was not confirmed in two other trials, and the relationship between 5-alpha reductase inhibitors and Gleason score in incident prostate cancer remains unsettled. (See
         <a class="medical medical_review" href="/z/d/html/6949.html" rel="external">
          "Chemoprevention strategies in prostate cancer", section on '5-Alpha reductase inhibitors'
         </a>
         .)
        </p>
        <p>
         Administration of a 5-alpha reductase inhibitor may complicate the diagnosis of a prostate cancer because these agents produce a nearly 50 percent decrease in serum PSA concentrations during the first three months of therapy, which persists as long as the drug is continued. (See
         <a class="medical medical_review" href="/z/d/html/7568.html" rel="external">
          "Measurement of prostate-specific antigen", section on 'Medications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h2">
          Radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radiation therapy (RT) including both external beam and brachytherapy will cause significant cytologic damage to prostate cancer cells as well as benign prostatic stromal and epithelial cells. The majority of series describing the histologic appearance of the irradiated prostate glands were derived from patients receiving external beam RT [
         <a href="#rid154">
          154,155
         </a>
         ]. Histologic changes following brachytherapy are similar but may be more pronounced [
         <a href="#rid155">
          155,156
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6923.html" rel="external">
          "Brachytherapy for low-risk or favorable intermediate-risk, clinically localized prostate cancer"
         </a>
         .)
        </p>
        <p>
         Postradiation biopsy is not routine following RT but may be indicated only if the PSA is rising, recurrent disease is suspected, and salvage surgery or brachytherapy is being considered. (See
         <a class="medical medical_review" href="/z/d/html/6932.html" rel="external">
          "Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy", section on 'General approach'
         </a>
         .)
        </p>
        <p>
         Several weeks after RT, prostatic cells undergo severe degenerative changes, including nuclear shrinkage and cytoplasmic damage. Occasionally, small foci of necrosis will be evident, both in benign and malignant glands. Acute inflammatory cells, such as neutrophils, macrophages, and later lymphocytes, accumulate. Gradually, the infiltration of reactive cells subsides, and fibrosis develops in areas of tissue damage. Prostate biopsy is rarely done in the acute phase within six months after radiation because it does not provide significant clinical information.
        </p>
        <p>
         In response to RT, benign epithelial and stromal cells develop cytologic atypia, with the epithelial cells showing prominent nuclear irregularity, hyperchromasia, and polymorphic changes  (
         <a class="graphic graphic_table graphicRef50546" href="/z/d/graphic/50546.html" rel="external">
          table 7
         </a>
         ). Because of the presence of smudged nuclei, prominent nucleoli are not commonly seen. Irradiated benign epithelial cells often show a slightly spindled appearance, termed "streaming" histology. Despite marked nuclear atypia, benign glands still retain their lobular noninfiltrating patterns  (
         <a class="graphic graphic_picture graphicRef66055" href="/z/d/graphic/66055.html" rel="external">
          picture 17
         </a>
         ). Irradiated tumor cells may display clear cytoplasm and other degenerative changes, or they may show no apparent histologic changes from the radiation  (
         <a class="graphic graphic_picture graphicRef64711" href="/z/d/graphic/64711.html" rel="external">
          picture 18
         </a>
         ).
        </p>
        <p>
         Nonspecific histologic changes, such as chronic inflammation, basal cell proliferation, or stromal fibrosis, may also be present to varying degrees. Postradiation changes in the benign glands may persist for many years following prostatic RT, causing difficulty interpreting prostate biopsies in irradiated men [
         <a href="#rid156">
          156
         </a>
         ]. In diagnostically difficult cases, immunostaining specific for basal cells (p63 and high molecular weight keratins) may be helpful, often showing positive staining in the benign atypical cells but not in malignant cells.
        </p>
        <p>
         Whether the Gleason grade of recurrent adenocarcinoma following a course of RT accurately reflects tumor aggressiveness or clinical behavior is uncertain [
         <a href="#rid157">
          157
         </a>
         ]. In general, current recommendation is to report the Gleason score and grade group in cases with no obvious histologic evidence of treatment effect on the prostatic adenocarcinoma cells. How to grade and report the cases of prostatic adenocarcinoma with obvious treatment effects is still in debate. Further studies are necessary to evaluate this issue.
        </p>
        <p>
         In contrast to the benign glands, the characteristic haphazard infiltrating architectural pattern and cytologic features of malignant prostate glands are often retained  (
         <a class="graphic graphic_table graphicRef50546" href="/z/d/graphic/50546.html" rel="external">
          table 7
         </a>
         ) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         The presence of malignant cells six months following RT to the prostate should not be interpreted as treatment failure. The long doubling time of many prostate tumors, coupled with radiobiologic data indicating that cell death following RT is a postmitotic event, suggests that the time course of disappearance of viable cancer from the prostate is prolonged. As a result, false-positive biopsies may be due to delayed tumor regression, and indeterminate biopsies (usually showing radiation effect in viable tumor cells) are of uncertain significance. In one series, for example, 30 percent of indeterminate biopsies showed eventual clearance of tumor at a mean time of 30 months following RT [
         <a href="#rid158">
          158
         </a>
         ]. A higher number of indeterminate biopsies may convert to negative in men undergoing brachytherapy [
         <a href="#rid159">
          159
         </a>
         ].
        </p>
        <p>
         A biopsy that demonstrates the presence of tumor cells beyond 18 to 24 months is more likely to indicate active disease (either persistence or a local recurrence) [
         <a href="#rid157">
          157,159,160
         </a>
         ]; however, even this is not absolute. In at least one series, 22 of 46 men who underwent routine prostate biopsy after combined external beam RT and brachytherapy had evidence of residual tumor cells; however, 16 had no evidence of an elevated serum PSA (biochemical failure) [
         <a href="#rid157">
          157
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Biopsy technique
         </strong>
         – Core needle biopsy of the prostate is essential to determine whether or not cancer is present in men with an elevated serum prostate-specific antigen level and/or an abnormal digital rectal examination. The standard is to take multiple core biopsies under transrectal ultrasound guidance. Primary diagnosis of prostate cancer using fine-needle aspiration is not acceptable in the United States, although it was widely used in other countries in the past. (See
         <a class="local">
          'Biopsy technique'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Histology
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         More than 95 percent of malignancies arising in the prostate are adenocarcinomas. The remaining types include neoplasms with neuroendocrine differentiation, urothelial carcinoma, basal cell carcinoma, lymphoma, and sarcoma. (See
         <a class="local">
          'Histologic features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A definitive pathologic diagnosis of prostate cancer is usually needed for clinical management, but definitive diagnosis is not always possible. The accuracy of pathologic diagnosis of prostate cancer can be improved by assessing deeper sections and by using immunohistochemistry (IHC) markers; correct interpretation of the IHC results is critical for success. (See
         <a class="local">
          'Cases with diagnostic uncertainty'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Several factors can have a significant effect on this histologic appearance of a prostate biopsy specimen, especially cancer treatment  (
         <a class="graphic graphic_table graphicRef50546" href="/z/d/graphic/50546.html" rel="external">
          table 7
         </a>
         ). (See
         <a class="local">
          'Effect of treatment on biopsy specimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Key features of the pathology report
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Besides histologic type, additional information that may be derived from a prostate biopsy includes the number of positive cores, the percentage (or length) of cancer in the positive core, the presence of perineural invasion or extraprostatic extension, and the presence of histologic types other than conventional adenocarcinoma. (See
         <a class="local">
          'When cancer is present'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Even if invasive cancer cannot be determined with certainty on the diagnostic prostate biopsy, several benign features, including prostatic intraepithelial neoplasia and benign prostatic hyperplasia, warrant mention in the pathology report. (See
         <a class="local">
          'When cancer is absent'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         When prostatic adenocarcinoma is present in the biopsy, histologic grading is accomplished using the Gleason score, which is based on the architectural features of the prostate cancer cells. Gleason scoring is not applicable to other histologic tumor types.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The Gleason grades for the two most prevalent differentiation patterns have been used to create the Gleason score, and this is now being used in the newly adopted grade group system  (
         <a class="graphic graphic_table graphicRef107132" href="/z/d/graphic/107132.html" rel="external">
          table 4
         </a>
         ). This information correlates closely with clinical behavior, and a grade group system has been incorporated into the 2017 Tumor, Node, Metastasis prognostic group staging system for prostate cancer  (
         <a class="graphic graphic_table graphicRef110728" href="/z/d/graphic/110728.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef110729" href="/z/d/graphic/110729.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Gleason grading system'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/16992.html" rel="external">
          "Initial staging and evaluation of males with newly diagnosed prostate cancer", section on 'Staging system'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         There is no consensus whether the clinical management decision should be based on the highest score (grade group) of one part or on the overall (global) Gleason score (grade group) in a prostate biopsy. However, if a Gleason 5 tumor component is present in the biopsy specimen such as in 3+5 and 4+5, the highest score should be considered primarily. For Gleason score 4+3, 4+4, or 3+4, the decision should be mostly decided on the individual basis considering the foci of these higher grade tumors with Gleason 4 component could be very small. (See
         <a class="local">
          'Gleason score'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Artificial intelligence-based software systems are a promising tool to aid pathologists in making an accurate diagnosis of prostate cancer, but they cannot replace review of histologic material by a trained pathologist. (See
         <a class="local">
          'Application of artificial intelligence in detection of prostate cancer'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2757615593">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         We are saddened by the death of Nicholas Vogelzang, MD, who passed away in September 2022. UpToDate gratefully acknowledges Dr. Vogelzang's role as Section Editor on this topic, and his dedicated and longstanding involvement with the UpToDate program.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med 1993; 118:804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91:1017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer BS, Brown ML, Prorok PC, et al. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993; 119:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li YH, Elshafei A, Li J, et al. Potential benefit of transrectal saturation prostate biopsy as an initial biopsy strategy: decreased likelihood of finding significant cancer on future biopsy. Urology 2014; 83:714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madrigal AG, Ross J, Yang X. Correlation of PI-RADS in targeted prostate biopsy with pathologic features of prostate cancer. Mod Pathol 2018; 31:361.
          </a>
         </li>
         <li class="breakAll">
          Epstein JI, Yang XJ. Prostate biopsy interpretation, 3rd ed, Lippincott, Williams, and Wilkins, Philadelphia 2002.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chow K, Bedő J, Ryan A, et al. Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival. Eur J Cancer 2021; 148:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varma M, Lee MW, Tamboli P, et al. Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens. A study of 250 consecutive cases in a routine surgical pathology practice. Arch Pathol Lab Med 2002; 126:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res 1985; 45:3663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 1989; 13:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang XJ, Lecksell K, Gaudin P, Epstein JI. Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer. Am J Surg Pathol 1999; 23:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu J, Stolk JA, Zhang X, et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 2000; 60:1677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang Z, Woda BA, Rock KL, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 2001; 25:1397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin MA, Zhou M, Dhanasekaran SM, et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287:1662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo J, Zha S, Gage WR, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002; 62:2220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang Z, Wu CL, Woda BA, et al. P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol 2002; 26:1169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang XJ, Laven B, Tretiakova M, et al. Detection of alpha-methylacyl-coenzyme A racemase in postradiation prostatic adenocarcinoma. Urology 2003; 62:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang XJ, Wu CL, Woda BA, et al. Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol 2002; 26:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beach R, Gown AM, De Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol 2002; 26:1588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah RB, Zhou M, LeBlanc M, et al. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol 2002; 26:1161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurel B, Ali TZ, Montgomery EA, et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol 2010; 34:1097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chuang AY, DeMarzo AM, Veltri RW, et al. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol 2007; 31:1246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bander NH, Nanus DM, Milowsky MI, et al. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003; 30:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allhoff EP, Proppe KH, Chapman CM, et al. Evaluation of prostate specific acid phosphatase and prostate specific antigen in identification of prostatic cancer. J Urol 1983; 129:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalos M, Askaa J, Hylander BL, et al. Prostein expression is highly restricted to normal and malignant prostate tissues. Prostate 2004; 60:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaux A, Albadine R, Toubaji A, et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol 2011; 35:1014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magi-Galluzzi C, Tsusuki T, Elson P, et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 2011; 71:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suh JH, Park JW, Lee C, Moon KC. ERG immunohistochemistry and clinicopathologic characteristics in Korean prostate adenocarcinoma patients. Korean J Pathol 2012; 46:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou CK, Young D, Yeboah ED, et al. TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences. Am J Epidemiol 2017; 186:1352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           He H, Magi-Galluzzi C, Li J, et al. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer". Am J Surg Pathol 2011; 35:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheble VJ, Braun M, Beroukhim R, et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 2010; 23:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brooks JD, Wei W, Hawley S, et al. Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. PLoS One 2015; 10:e0132343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein JI, Amin MB, Beltran H, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 2014; 38:756.
          </a>
         </li>
         <li class="breakAll">
          Srigley JR, Rubin MA. Neuroendocrine neoplasms. In: WHO Classification of tumours: Urinary and Male Genital Tumors, 5, Menon S, Moch H (Eds), International Agency for Research on Cancer, Lyon 2022. Vol 8.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mucci NR, Akdas G, Manely S, Rubin MA. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol 2000; 31:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol 2014; 2:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 1999; 6:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           di Sant'Agnese PA, de Mesy Jensen KL. Neuroendocrine differentiation in prostatic carcinoma. Hum Pathol 1987; 18:849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol 2001; 12 Suppl 2:S135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamas EF, Epstein JI. Prognostic significance of paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate. Am J Surg Pathol 2006; 30:980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996; 27:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casella R, Bubendorf L, Sauter G, et al. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. J Urol 1998; 160:406.
          </a>
         </li>
         <li class="breakAll">
          Netto GJ, Amin MB, Kench JG. Tumours of the prostate. In: WHO Classification of Tumours: Urinary and Male Genital Tumours, 5, Srigley JR, Tsuzuki T, Rubin MA (Eds), International Agency for Research on Cancer, Lyon 2022. Vol 8.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aparicio AM, Harzstark AL, Corn PG, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013; 19:3621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reyes A, Moran CA. Low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate. Arch Pathol Lab Med 2004; 128:e166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goulet-Salmon B, Berthe E, Franc S, et al. Prostatic neuroendocrine tumor in multiple endocrine neoplasia Type 2B. J Endocrinol Invest 2004; 27:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Têtu B, Ro JY, Ayala AG, et al. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer 1987; 59:1803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lotan TL, Gupta NS, Wang W, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011; 24:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schelling LA, Williamson SR, Zhang S, et al. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. Hum Pathol 2013; 44:2227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mackey JR, Au HJ, Hugh J, Venner P. Genitourinary small cell carcinoma: determination of clinical and therapeutic factors associated with survival. J Urol 1998; 159:1624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ordóñez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol 2000; 24:1217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agoff SN, Lamps LW, Philip AT, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol 2000; 13:238.
          </a>
         </li>
         <li class="breakAll">
          WHO Classification of Tumours of the Urinary System and Mail Genital Organs, 4th ed, Moch H, Humphrey PA, Ulbright TM, Reuter VE (Eds), WHO, Lyon 2016.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans AJ, Humphrey PA, Belani J, et al. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol 2006; 30:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guo CC, Epstein JI. Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance. Mod Pathol 2006; 19:1528.
          </a>
         </li>
         <li class="breakAll">
          Epstein JI, Oxley J, Ro JY, et al. Intraductal carcinoma. In: WHO classification of tumours of the urinary system and male genital organs, 4th ed, Moch H, Humphrey PA, Ulbright TM, Reuter VE (Eds), World Health Organization, Lyon 2016. p.164.
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Leenders GJLH, van der Kwast TH, Grignon DJ, et al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol 2020; 44:e87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson BD, Epstein JI. Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. J Urol 2010; 184:1328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou M. High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate. Mod Pathol 2018; 31:S71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimura K, Tsuzuki T, Kato M, et al. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate 2014; 74:680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen RJ, McNeal JE, Baillie T. Patterns of differentiation and proliferation in intraductal carcinoma of the prostate: significance for cancer progression. Prostate 2000; 43:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah RB, Magi-Galluzzi C, Han B, Zhou M. Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies. Am J Surg Pathol 2010; 34:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khani F, Epstein JI. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes. Am J Surg Pathol 2015; 39:1383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miura N, Mori K, Mostafaei H, et al. The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis. J Urol 2020; 204:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh DL, Chang SS. Dilemmas in the treatment of urothelial cancers of the prostate. Urol Oncol 2009; 27:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bostwick DG. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 1994; 18:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein JI. An update of the Gleason grading system. J Urol 2010; 183:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 2016; 40:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol 2016; 69:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berney DM, Beltran L, Fisher G, et al. Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome. Br J Cancer 2016; 114:1078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ham WS, Chalfin HJ, Feng Z, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. Eur Urol 2017; 71:907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carter HB, Partin AW, Walsh PC, et al. Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol 2012; 30:4294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein JI, Amin MB, Fine SW, et al. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Arch Pathol Lab Med 2021; 145:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein JI, Kryvenko ON. A Comparison of Genitourinary Society Pathology and International Society of Urological Pathology Prostate Cancer Guidelines. Eur Urol 2021; 79:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin MA, Dunn R, Kambham N, et al. Should a Gleason score be assigned to a minute focus of carcinoma on prostate biopsy? Am J Surg Pathol 2000; 24:1634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crawford ED, Grubb R 3rd, Black A, et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol 2011; 29:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matoso A, Epstein JI. Defining clinically significant prostate cancer on the basis of pathological findings. Histopathology 2019; 74:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nickel JC, Speakman M. Should we really consider Gleason 6 prostate cancer? BJU Int 2012; 109:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eggener SE, Berlin A, Vickers AJ, et al. Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. J Clin Oncol 2022; 40:3110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donin NM, Laze J, Zhou M, et al. Gleason 6 prostate tumors diagnosed in the PSA era do not demonstrate the capacity for metastatic spread at the time of radical prostatectomy. Urology 2013; 82:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson BB, Oberlin DT, Razmaria AA, et al. Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer. Eur Urol 2017; 72:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheridan TB, Carter HB, Wang W, et al. Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol 2008; 179:901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popiolek M, Rider JR, Andrén O, et al. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol 2013; 63:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tollefson MK, Leibovich BC, Slezak JM, et al. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol 2006; 175:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang DE, Fitzsimons NJ, Presti JC Jr, et al. Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database. Urology 2007; 70:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burdick MJ, Reddy CA, Ulchaker J, et al. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer. Int J Radiat Oncol Biol Phys 2009; 73:1439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stark JR, Perner S, Stampfer MJ, et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 2009; 27:3459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright JL, Salinas CA, Lin DW, et al. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol 2009; 182:2702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koontz BF, Tsivian M, Mouraviev V, et al. Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers. Int J Radiat Oncol Biol Phys 2012; 82:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vira MA, Tomaszewski JE, Hwang WT, et al. Impact of the percentage of positive biopsy cores on the further stratification of primary grade 3 and grade 4 Gleason score 7 tumors in radical prostatectomy patients. Urology 2005; 66:1015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalgo ML, Bastian PJ, Mangold LA, et al. Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. Urology 2006; 67:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huynh MA, Chen MH, Wu J, et al. Gleason Score 3 + 5 or 5 + 3 versus 4 + 4 Prostate Cancer: The Risk of Death. Eur Urol 2016; 69:976.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein JI, Allsbrook WC Jr, Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29:1228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel AA, Chen MH, Renshaw AA, D'Amico AV. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA 2007; 298:1533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adam M, Hannah A, Budäus L, et al. A tertiary Gleason pattern in the prostatectomy specimen and its association with adverse outcome after radical prostatectomy. J Urol 2014; 192:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Özsoy M, D'Andrea D, Moschini M, et al. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer. Urol Oncol 2018; 36:158.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng L, Davidson DD, Lin H, Koch MO. Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy. Cancer 2007; 110:1967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005; 97:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell RE, Shah JB, Desai M, et al. Changes in prognostic significance and predictive accuracy of Gleason grading system throughout PSA era: impact of grade migration in prostate cancer. Urology 2007; 70:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jani AB, Johnstone PA, Liauw SL, et al. Age and grade trends in prostate cancer (1974-2003): a Surveillance, Epidemiology, and End Results Registry analysis. Am J Clin Oncol 2008; 31:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burchardt M, Engers R, Müller M, et al. Interobserver reproducibility of Gleason grading: evaluation using prostate cancer tissue microarrays. J Cancer Res Clin Oncol 2008; 134:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hesterberg AB, Gordetsky JB, Hurley PJ. Cribriform Prostate Cancer: Clinical Pathologic and Molecular Considerations. Urology 2021; 155:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dong F, Yang P, Wang C, et al. Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma. Am J Surg Pathol 2013; 37:1855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo X, Khurana JS, Jhala N, et al. The Association of Invasive Cribriform Lesions With Adverse Prostatic Adenocarcinoma Outcomes: An Institutional Experience, Systematic Review, and Meta-analysis. Arch Pathol Lab Med 2019; 143:1012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanwick JM, Dalkin BL, Nagle RB. Accuracy of prostate needle biopsy in predicting extracapsular tumor extension at radical retropubic prostatectomy: application in selecting patients for nerve-sparing surgery. Urology 1998; 52:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sebo TJ, Cheville JC, Riehle DL, et al. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer 2001; 91:2196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Egevad L, Norberg M, Mattson S, et al. Estimation of prostate cancer volume by multiple core biopsies before radical prostatectomy. Urology 1998; 52:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis JS Jr, Vollmer RT, Humphrey PA. Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screening population. Am J Clin Pathol 2002; 118:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freedland SJ, Aronson WJ, Csathy GS, et al. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Urology 2003; 61:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dong F, Jones JS, Stephenson AJ, et al. Prostate cancer volume at biopsy predicts clinically significant upgrading. J Urol 2008; 179:896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Amico AV, Wu Y, Chen MH, et al. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer. J Urol 2001; 165:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmes GF, Walsh PC, Pound CR, Epstein JI. Excision of the neurovascular bundle at radical prostatectomy in cases with perineural invasion on needle biopsy. Urology 1999; 53:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee IH, Roberts R, Shah RB, et al. Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer. Int J Radiat Oncol Biol Phys 2007; 68:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vargas SO, Jiroutek M, Welch WR, et al. Perineural invasion in prostate needle biopsy specimens. Correlation with extraprostatic extension at resection. Am J Clin Pathol 1999; 111:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de la Taille A, Katz A, Bagiella E, et al. Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage. Urology 1999; 54:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson PR, Hanlon AL, Patchefsky A, et al. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA &lt;10 ng/ml treated with conformal external beam radiation therapy. Int J Radiat Oncol Biol Phys 1998; 41:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harnden P, Shelley MD, Clements H, et al. The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review. Cancer 2007; 109:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Malley KJ, Pound CR, Walsh PC, et al. Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy. Urology 2002; 59:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu HH, Song DY, Tsai YY, et al. Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy. Urology 2007; 70:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bostwick DG, Kindrachuk RW, Rouse RV. Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings. Am J Surg Pathol 1985; 9:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oxley JD, Abbott CD, Gillatt DA, MacIver AG. Ductal carcinomas of the prostate: a clinicopathological and immunohistochemical study. Br J Urol 1998; 81:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amin A, Epstein JI. Pathologic stage of prostatic ductal adenocarcinoma at radical prostatectomy: effect of percentage of the ductal component and associated grade of acinar adenocarcinoma. Am J Surg Pathol 2011; 35:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neal DE Jr, Clejan S, Sarma D, Moon TD. Prostate specific antigen and prostatitis. I. Effect of prostatitis on serum PSA in the human and nonhuman primate. Prostate 1992; 20:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okada K, Kojima M, Naya Y, et al. Correlation of histological inflammation in needle biopsy specimens with serum prostate- specific antigen levels in men with negative biopsy for prostate cancer. Urology 2000; 55:892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oppenheimer JR, Kahane H, Epstein JI. Granulomatous prostatitis on needle biopsy. Arch Pathol Lab Med 1997; 121:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milord RA, Kahane H, Epstein JI. Infarct of the prostate gland: experience on needle biopsy specimens. Am J Surg Pathol 2000; 24:1378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasui Y, Marutsuka K, Asada Y, et al. Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. Prostate 1994; 25:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viglione MP, Potter S, Partin AW, et al. Should the diagnosis of benign prostatic hyperplasia be made on prostate needle biopsy? Hum Pathol 2002; 33:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iczkowski KA, Cheng L, Qian J, et al. ASAP is a valid diagnosis. Atypical small acinar proliferation. Hum Pathol 1999; 30:1403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006; 175:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iczkowski KA, MacLennan GT, Bostwick DG. Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: clinical significance in 33 cases. Am J Surg Pathol 1997; 21:1489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan TY, Epstein JI. Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology 1999; 53:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein JI. Atypical small acinar proliferation of the prostate gland. Am J Surg Pathol 1998; 22:1430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'dowd GJ, Miller MC, Orozco R, Veltri RW. Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology 2000; 55:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peng Y, Jiang Y, Chuang ST, Yang XJ. Computer-aided detection of prostate cancer on tissue sections. Appl Immunohistochem Mol Morphol 2009; 17:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raciti P, Sue J, Ceballos R, et al. Novel artificial intelligence system increases the detection of prostate cancer in whole slide images of core needle biopsies. Mod Pathol 2020; 33:2058.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perincheri S, Levi AW, Celli R, et al. An independent assessment of an artificial intelligence system for prostate cancer detection shows strong diagnostic accuracy. Mod Pathol 2021; 34:1588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mata LA, Retamero JA, Gupta RT, et al. Artificial Intelligence-assisted Prostate Cancer Diagnosis: Radiologic-Pathologic Correlation. Radiographics 2021; 41:1676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           da Silva LM, Pereira EM, Salles PG, et al. Independent real-world application of a clinical-grade automated prostate cancer detection system. J Pathol 2021; 254:147.
          </a>
         </li>
         <li class="breakAll">
          https://www.fda.gov/news-events/press-announcements/fda-authorizes-software-can-help-identify-prostate-cancer (Accessed on November 10, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steiner DF, Nagpal K, Sayres R, et al. Evaluation of the Use of Combined Artificial Intelligence and Pathologist Assessment to Review and Grade Prostate Biopsies. JAMA Netw Open 2020; 3:e2023267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Têtu B, Srigley JR, Boivin JC, et al. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. Am J Surg Pathol 1991; 15:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armas OA, Aprikian AG, Melamed J, et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 1994; 18:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vernon SE, Williams WD. Pre-treatment and post-treatment evaluation of prostatic adenocarcinoma for prostatic specific acid phosphatase and prostatic specific antigen by immunohistochemistry. J Urol 1983; 130:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang XJ, Lecksell K, Short K, et al. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1999; 53:696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iczkowski KA, Qiu J, Qian J, et al. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology 2005; 65:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carver BS, Kattan MW, Scardino PT, Eastham JA. Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. BJU Int 2005; 95:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin MA, Allory Y, Molinié V, et al. Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology 2005; 66:930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gleave M, Qian J, Andreou C, et al. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study. Prostate 2006; 66:1674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andriole G, Bostwick D, Civantos F, et al. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol 2005; 174:2098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bostwick DG, Egbert BM, Fajardo LF. Radiation injury of the normal and neoplastic prostate. Am J Surg Pathol 1982; 6:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaudin PB, Zelefsky MJ, Leibel SA, et al. Histopathologic effects of three-dimensional conformal external beam radiation therapy on benign and malignant prostate tissues. Am J Surg Pathol 1999; 23:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magi-Galluzzi C, Sanderson H, Epstein JI. Atypia in nonneoplastic prostate glands after radiotherapy for prostate cancer: duration of atypia and relation to type of radiotherapy. Am J Surg Pathol 2003; 27:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldstein NS, Martinez A, Vicini F, Stromberg J. The histology of radiation therapy effect on prostate adenocarcinoma as assessed by needle biopsy after brachytherapy boost. Correlation with biochemical failure. Am J Clin Pathol 1998; 110:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crook J, Malone S, Perry G, et al. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000; 48:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prestidge BR, Hoak DC, Grimm PD, et al. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stock RG, Stone NN, Kao J, et al. The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy: implications for treatment optimization. Cancer 2000; 89:1829.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6924 Version 47.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7682387" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Prostate cancer: screening, diagnosis, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10379964" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7692780" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Prostate cancer screening: what we know and what we need to know.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24680442" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Potential benefit of transrectal saturation prostate biopsy as an initial biopsy strategy: decreased likelihood of finding significant cancer on future biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Correlation of PI-RADS in targeted prostate biopsy with pathologic features of prostate cancer
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Correlation of PI-RADS in targeted prostate biopsy with pathologic features of prostate cancer
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33678516" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11958660" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens. A study of 250 consecutive cases in a routine surgical pathology practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2410099" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Keratin immunoreactivity in the benign and neoplastic human prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2469333" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9989840" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10749139" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Identification of differentially expressed genes in human prostate cancer using subtraction and microarray.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11684956" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : P504S: a new molecular marker for the detection of prostate carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11926890" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11956072" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12218573" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12893336" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Detection of alpha-methylacyl-coenzyme A racemase in postradiation prostatic adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12131160" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12459625" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12218572" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20588175" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : NKX3.1 as a marker of prostatic origin in metastatic tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17667550" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14571414" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6339742" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Evaluation of prostate specific acid phosphatase and prostate specific antigen in identification of prostatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15176054" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Prostein expression is highly restricted to normal and malignant prostate tissues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21677539" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20878952" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23136568" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : ERG immunohistochemistry and clinicopathologic characteristics in Korean prostate adenocarcinoma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28633309" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21383613" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20473283" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26172920" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24705311" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24705311" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10821485" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25606573" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Neuroendocrine differentiation of prostate cancer: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10730904" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Neuroendocrine cells in tumour growth of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3610135" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Neuroendocrine differentiation in prostatic carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11762341" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16861969" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prognostic significance of paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8698312" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9679888" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9679888" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23649003" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Platinum-based chemotherapy for variant castrate-resistant prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15578903" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15717656" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Prostatic neuroendocrine tumor in multiple endocrine neoplasia Type 2B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3030528" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21336263" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : ERG gene rearrangements are common in prostatic small cell carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23850495" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9554367" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Genitourinary small cell carcinoma: determination of clinical and therapeutic factors associated with survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10976695" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10757334" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10757334" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16723845" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16980940" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16980940" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32459716" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20723921" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29297491" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24481730" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10725861" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Patterns of differentiation and proliferation in intraductal carcinoma of the prostate: significance for cancer progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20182345" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26076065" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32698712" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18439852" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Dilemmas in the treatment of urothelial cancers of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4813554" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8037294" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20006878" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : An update of the Gleason grading system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26492179" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26166626" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27100731" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27876305" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23032616" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Gleason score 6 adenocarcinoma: should it be labeled as cancer?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32589068" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33189461" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : A Comparison of Genitourinary Society Pathology and International Society of Urological Pathology Prostate Cancer Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11117784" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Should a Gleason score be assigned to a minute focus of carcinoma on prostate biopsy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19297566" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Screening and prostate-cancer mortality in a randomized European study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21041707" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Comorbidity and mortality results from a randomized prostate cancer screening trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30565298" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Defining clinically significant prostate cancer on the basis of pathological findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22193242" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Should we really consider Gleason 6 prostate cancer?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35436144" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Low-Grade Prostate Cancer: Time to Stop Calling It Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23706588" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Gleason 6 prostate tumors diagnosed in the PSA era do not demonstrate the capacity for metastatic spread at the time of radical prostatectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27986368" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18207195" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Change in prostate cancer grade over time in men followed expectantly for stage T1c disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23084329" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Natural history of early, localized prostate cancer: a final report from three decades of follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16406993" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17826489" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18963536" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19433685" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19836772" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21237582" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16286115" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Impact of the percentage of positive biopsy cores on the further stratification of primary grade 3 and grade 4 Gleason score 7 tumors in radical prostatectomy patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16413345" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26388503" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Gleason Score 3 + 5 or 5 + 3 versus 4 + 4 Prostate Cancer: The Risk of Death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16096414" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17911498" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24518778" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : A tertiary Gleason pattern in the prostatectomy specimen and its association with adverse outcome after radical prostatectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29288003" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17823907" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16145045" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Prostate cancer and the Will Rogers phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17707892" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Changes in prognostic significance and predictive accuracy of Gleason grading system throughout PSA era: impact of grade migration in prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18845997" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Age and grade trends in prostate cancer (1974-2003): a Surveillance, Epidemiology, and End Results Registry analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18392850" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Interobserver reproducibility of Gleason grading: evaluation using prostate cancer tissue microarrays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34058243" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Cribriform Prostate Cancer: Clinical Pathologic and Molecular Considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24145642" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30702333" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : The Association of Invasive Cribriform Lesions With Adverse Prostatic Adenocarcinoma Outcomes: An Institutional Experience, Systematic Review, and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9801105" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Accuracy of prostate needle biopsy in predicting extracapsular tumor extension at radical retropubic prostatectomy: application in selecting patients for nerve-sparing surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11391602" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9763088" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Estimation of prostate cancer volume by multiple core biopsies before radical prostatectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12219787" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screening population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12670558" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18207180" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Prostate cancer volume at biopsy predicts clinically significant upgrading.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11125380" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10197851" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Excision of the neurovascular bundle at radical prostatectomy in cases with perineural invasion on needle biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17398032" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9930144" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Perineural invasion in prostate needle biopsy specimens. Correlation with extraprostatic extension at resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10604705" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9719119" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA&lt;10 ng/ml treated with conformal external beam radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17123267" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11796287" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17656219" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4091189" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9467486" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Ductal carcinomas of the prostate: a clinicopathological and immunohistochemical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21383610" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Pathologic stage of prostatic ductal adenocarcinoma at radical prostatectomy: effect of percentage of the ductal component and associated grade of acinar adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1372426" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Prostate specific antigen and prostatitis. I. Effect of prostatitis on serum PSA in the human and nonhuman primate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10840104" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Correlation of histological inflammation in needle biopsy specimens with serum prostate- specific antigen levels in men with negative biopsy for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9240909" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Granulomatous prostatitis on needle biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11023099" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Infarct of the prostate gland: experience on needle biopsy specimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7518599" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12203211" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Should the diagnosis of benign prostatic hyperplasia be made on prostate needle biopsy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10667415" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : ASAP is a valid diagnosis. Atypical small acinar proliferation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16469560" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9414193" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: clinical significance in 33 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9933053" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Follow-up of atypical prostate needle biopsies suspicious for cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9808137" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Atypical small acinar proliferation of the prostate gland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10736500" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Analysis of repeated biopsy results within 1 year after a noncancer diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19417626" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Computer-aided detection of prostate cancer on tissue sections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32393768" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Novel artificial intelligence system increases the detection of prostate cancer in whole slide images of core needle biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33782551" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : An independent assessment of an artificial intelligence system for prostate cancer detection shows strong diagnostic accuracy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34597215" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Artificial Intelligence-assisted Prostate Cancer Diagnosis: Radiologic-Pathologic Correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33904171" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Independent real-world application of a clinical-grade automated prostate cancer detection system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33904171" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Independent real-world application of a clinical-grade automated prostate cancer detection system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33180129" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Evaluation of the Use of Combined Artificial Intelligence and Pathologist Assessment to Review and Grade Prostate Biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1989458" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7522415" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6191050" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Pre-treatment and post-treatment evaluation of prostatic adenocarcinoma for prostatic specific acid phosphatase and prostatic specific antigen by immunohistochemistry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10197843" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15667867" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15705069" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16286097" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16927304" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16280736" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12824459" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : The influence of finasteride on the development of prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7149094" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Radiation injury of the normal and neoplastic prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10478661" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Histopathologic effects of three-dimensional conformal external beam radiation therapy on benign and malignant prostate tissues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12548167" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Atypia in nonneoplastic prostate glands after radiotherapy for prostate cancer: duration of atypia and relation to type of radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9844589" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : The histology of radiation therapy effect on prostate adenocarcinoma as assessed by needle biopsy after brachytherapy boost. Correlation with biochemical failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10974448" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9054874" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11042580" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy: implications for treatment optimization.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
